GMG Unveils Graphene Aluminium-Ion Battery That Fully Charges in 6 Minutes ACN Newswire

GMG Unveils Graphene Aluminium-Ion Battery That Fully Charges in 6 Minutes

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - December 15, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to provide the latest progress update on the Graphene Aluminium-Ion Battery technology ("G+AI") being developed by GMG and the University of Queensland ("UQ") under a Joint Development Agreement with Rio Tinto, one of the world's largest metals and mining groups, and with the support of the Battery Innovation Center of Indiana ("BIC") in the United States of America.Based on its current state of development as reflected below, the GMG G+AI Battery has similar performance characteristics to those provided by High Power Lithium Titanate Oxide ("LTO") batteries, which are sold at a premium price of up to US$1500/kWh. However, the GMG G+AI Battery can be produced at a substantially lower cost and therefore can be priced below that of LTO batteries. In 2025, sales of LTO batteries, which are used in many applications globally, totalled US$ 5.6[1] billion.Battery Performance Update:GMG is pleased to announce that it has progressed its G+AI Battery technology and believes that, once development is completed, it can meet the key target specification requirements for the main targeted battery use case as per Figure 1, including:Charging in under 6 minutes;Energy density > 100 Wh/kg after 1 hour of charging;Long Cycle Life (10,000 cycles);Safe (no Lithium);Lower Thermal Runaway Risk; andLikely no thermal management system will be needed.Bob Galyen, GMG Non-Executive Director, commented: "In my nearly five decades in the battery industry, I have rarely seen a technology with the disruptive potential of GMG's next-generation graphene aluminium-ion battery. With the possibility of charging from empty to full in around six minutes, this chemistry fundamentally changes how designers can think about electric vehicles, consumer electronics, and stationary storage. Instead of planning around long charge stops with large packs, engineers can optimise for rapid energy turnaround, with higher power, and safer, with GMG's battery made from abundant raw materials. Lithium-ion will remain a key part of the energy landscape for years to come, but its limitations in fast charging, temperature tolerance, and critical-mineral supply are increasingly evident. By leveraging aluminium and graphene, the GMG team is demonstrating a pathway to reduce reliance on traditional lithium-based systems while delivering step-change improvements in charge time and power density. This is not an incremental tweak to existing cells - it is a new platform that can open markets and use cases that were previously uneconomic or impractical. As GMG moves from the lab toward scaled manufacturing, its primary focus is on proving reliability, safety, and cost at industrial level. Automotive, grid, and specialty-device partners are already engaging with GMG to explore pilot programs and early integrations. The companies that adapt quickest to this shift will lead the next wave of electrification, and GMG intends to be at the centre of that transition with graphene aluminium-ion technology."Figure 1: G+AI Battery Use Case - heavy mobile equipmentTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_gmg_figure1.jpgGMG is pleased to share the energy densities of the current GMG G+AI pouch cell at 60 minutes and 6-minute charging compared to other chemistry batteries on the market (Figure 2), and a voltage vs capacity graph (Figure 3) of its latest G+AI Battery technology based on data provided by the third-party BIC battery testing laboratory.Based on that testing, the current stage of development, batteries produced by GMG and BIC had an energy density of 58 Wh/kg when charged in 1 hour and 26 Wh/kg when charged in 6 minutes. In 6-minute fast charging, the battery cells achieved 62% capacity in 3.2 minutes. The batteries had a nominal voltage of approximately 3.0 Volts and maintained performance over hundreds of cycles at 6-minute fast charging, without the significant degradation typically observed in lithium and sodium-ion batteries at such high charging rates.Figure 2: Different Battery Chemistry Performance at 6 min and 60 min Charge[2]To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_002full.jpgStandard commercial Lithium Nickel Manganese Cobalt ("LNMC") and Lithium Iron Phosphate ("LFP") battery cells for electric vehicles and stationary storage are not designed for continuous 6-minute charging (10C); typical recommended charge rates are ≤1 hour (1C), often 2 hours (0.5C), with only limited fast charge operation. Only specialized high-power cell designs like LTO battery cells can tolerate charge rates of 6 minutes (10C).[3]Figure 3: Battery performance curves of GMG's G+AI Battery at 60 min and 6min chargeTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_003full.jpgGMG has now developed a completely new hybrid electrolyte that is chloride free and noncorrosive, unlike common aluminium battery electrolytes, along with a complex cathode and anode technology that enables very stable fast charging over several cycles. The substrate for both the cathode and anode in the GMG G+AI Battery is aluminium foil - which provides significant cost and weight savings compared with copper, the substrate material used in most lithium and sodium-ion batteries. GMG's technology does not include the use of lithium or copper. The Company has submitted an additional patent application covering these new developments.Craig Nicol, GMG Managing Director and CEO, commented: "I couldn't be happier with the GMG team to get to this point with our battery. We have rebuilt this battery in our weekly sprints from the ground up and developed completely new complex cathode, anode and electrolyte. This will provide a next generation fast charging battery technology currently not available in the world, and we look forward to sending out sample cells to test with partners in early 2026. This technology has many years of development in front of it and will improve as we keep pushing through known issues to improve capacity, voltage and reduce weight."GMG management believes that the Company's battery technology can eventually achieve over 150 Wh/kg when charged in 1 hour, and over 75 Wh/kg when charged in 6 minutes. The Company believes further development of the cathode, anode, electrolyte and component weights will eventually achieve this end goal.Figure 4 shows the latest Graphene Aluminium-Ion Battery multi-layer pouch cell.Figure 4: Current Multi-Layer Battery Pouch CellTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_004full.jpgBattery Technology Readiness LevelThe battery technology readiness level ("BTRL") of the G+AI technology remains at Level 4, see Figure 5. GMG is currently optimizing electrochemical behaviour for pouch cells via ongoing laboratory experimentation. Through collaboration with BIC, it is anticipated that the battery technology readiness will progress to BTRL 7 and 8 since the equipment and processes needed to produce the G+AI batteries are the same as those employed to make Lithium-Ion Batteries.Figure 5: Battery Technology Readiness Level (BTRL)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_005full.jpgThe Company is confident it can meet the overall timeline, as seen in Figure 6, of its battery cell roadmap that calls for testing of cells with customers in 2026 and small commercial production with support of various partners, including BIC, in 2027.Figure 6: Battery Cell RoadmapTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_006full.jpgNext Steps Toward Commercialisation & Market ApplicationsJack Perkowski, GMG Chairman and Non-Executive Director, commented: "I am extremely proud that GMG has progressed its battery to this stage. It is a significant milestone for the Company because the battery technology has so much opportunity in so many applications - especially in commercial vehicles. I look forward to the next updates as GMG makes further progress in the development of its battery technology."The Company continues to see a broad range of applications for a completed GMG G+AI Battery - utilising its ultra-high power-density and economic energy density characteristics. Along with Rio Tinto, a range of global companies have confidentially expressed their interest in working with GMG in the following vertical sectors:Figure 7: Market ApplicationsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_007full.jpgCurrently, GMG believes it will use a plastic battery pack design, similar to Figure 8, to hold the battery pouch cells - reducing the weight, cost and complexity of using a metal case. Using a plastic battery pack is possible for two main reasons - GMG believes that its battery will not require a thermal management system or the fireproofing precautions provided by the metal case in a lithium-ion battery. Using plastic will increase the comparative energy density of GMG's G+AI battery packs when compared to lithium-ion batteries.Figure 8: Expected Battery Pack for G+AIB Pouch CellsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_008full.jpgComparison and Market Review: LTO Batteries As shown in Figure 9 below, the performance of GMG's G+AI battery technology is already very similar to LTO batteries.Figure 9: Comparison of Graphene Aluminium-Ion Battery (G+AI) to Lithium Titanate Oxide (LTO) BatteryParameterHigh Power LTO[4]GMG G+AI BatteryRapid Charging80% in 6 minutes100% in 6 minutesEnergy Density - 6-minute charge37 Wh/kg (80% of Capacity)46 Wh/kg (6 min +)26 Wh/kg(Current)Large upside to be confirmedDepth of DischargeFull RangeFull RangeSafetySafeSafer (no lithium fire potential)Longevity70% performance over 20,000 cyclesTo be confirmedBattery PriceUS$800 - US$1500 / kWh[5]Lower price due to lower material costsNo lithium, no TitaniumMarket SizeUS$5.6 Billion in Sales in 2025Under development LTO batteries are sold at a premium to LFP and LNMC batteries, which are the main chemistries used in electric vehicles and energy storage systems, and are also widely used in other electronic applications due to their high performance and long cycle life. The material and manufacturing costs for GMG's G+AI Battery are expected to be similar to, or less than, the cost to manufacture standard lithium-ion batteries, but substantially lower than the costs to produce LTO batteries.LTO batteries have energy density ranging from 50 - 80 Wh/kg.[6] The LTO product is sold globally for use in many applications - with a total of US$5.6[7] billion sales per annum in 2025. Sales of LTO batteries are expected to grow at 10% per annum to an estimated US$ 9.0 billion by 2030. The major manufacturers of LTO batteries include Toshiba, Gree, Microvast and CATL.Further details on applications for the LTO battery from Mordor Intelligence7 are described below. In many of the use cases for LTO batteries, GMG believes that its G+AI Battery can be substituted at a substantially lower cost.Commercial Vehicles: Automotive, primarily buses, refuse trucks, and drayage tractors rather than passenger cars, is the largest user of LTO batteries. Fleets realize five-year total-cost-of-ownership parity once fuel savings and lower maintenance offset higher upfront prices.Fast-charging Electric Buses and Trucks: Transit authorities need battery systems that accept repeated high-power "opportunity charges" during short layovers. LTO cells replenish 80% capacity in roughly five minutes, allowing operators to shrink fleet size without sacrificing route frequency. U.S. Low-No Emission Bus grants earmark more than US$1.5 billion per year, with bid specifications that explicitly reference rapid-charge capability. Parallel subsidy programs in China reimburse up to CNY 80,000 (US$ 11,396) per new-energy bus, accelerating volume deployment in provincial capitals.Hybrid and BEV: Regenerative braking and high-C-rate acceleration favour the use of LTO batteries. Use in fast-charge EV stations is growing rapidly as ride-hailing fleets adopt swap-ready models.Stationary Storage: Utility-scale batteries now cycle multiple times per day for frequency regulation, peak shaving, and voltage support. Energy-storage-system integrators adopt LTO batteries for grid-frequency response where state-of-charge swings are shallow but frequent.Industrial Robotics: LTO batteries are used in continuous-duty forklifts that require partial charges during operator breaks.Aerospace and Defense: Unmanned aerial vehicles, missile auxiliaries, and soldier-worn power banks operating from -40 °C to +60 °C ambient.5-minute Battery-Swap Stations: Battery-as-a-service platforms require ultra-fast turnaround and high cycle life. CATL confirmed plans to install 1,000 swap stations in 2025 and 30,000-40,000 by 2030, each requiring packs that tolerate thousands of rapid exchanges without degradation.Sub-10 kWh Packs: Cordless construction tools, autonomous ground vehicles, and medical carts select LTO batteries to bypass daily pack swaps.12V starter replacement to Lead acid: GMG's G+AI battery technology would be a viable 12 V starter-battery replacement for lead-acid, offering lower weight, longer cycle life, good low-temperature performance and improved cold-cranking capability, together with excellent tolerance to storage at 0% state of charge. In suitable system designs, the chemistry's stable voltage behaviour can also reduce balancing requirements and simplify battery management, helping to lower overall system cost.Lifecycle Procurement Preference: Many government procurement frameworks now weigh lifecycle reliability higher than purchase price. For example, New Mexico awarded a US$ 400 million bus electrification contract that included stringent thermal-runaway resistance metrics. Europe's Clean Industrial Deal allocates capital for storage technologies that stabilize renewables, aligning well with LTO batteries' fast-response profile.Cylindrical Cells: accounted for 37.7% of LTO battery sales in 2024 as entrenched production lines and robust steel casings satisfied heavy-duty demand. Pouch designs address aerospace weight requirements and constrained dashboards in autonomous robots.Summary of Important Milestones for GMG's G+AI Battery Development: MonthImportant Milestones in the Development of the Graphene Aluminium Ion BatteryMay 2020GMG and UQ win Australian Research Council grant for Graphene battery developmenthttps://graphenemg.com/gmg-and-uq-wins-australian-research-council-grant-for-graphene-aluminium-ion-battery-development/ Apr 2021The University of Queensland and GMG kick off coin cell battery development projecthttps://graphenemg.com/gmg-the-university-of-queensland-research-uni-quest-kick-off-the-graphene-enhanced-aluminium-ion-battery-development-project/May 2021Graphene aluminium-ion battery performance data - Energy Density and Power Densityhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-performance-data/Jun 2021Graphene aluminium-ion battery performance data - Cycle Lifehttps://graphenemg.com/graphene-aluminium-ion-battery-performance-data/Jun 2021Significant potential battery customer market response to launch of batteryhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-progress-update/Jul 2021Investment decision for coin cell battery development centrehttps://graphenemg.com/gmg-battery-pilot-plant-investment/Oct 2021Construction starts for coin cell battery development centrehttps://graphenemg.com/construction-battery-pilotplant/Oct 2021Bosch Australia Manufacturing Solutions and GMG sign Letter of Intenthttps://graphenemg.com/gmg-and-bosch-sign-collaboration-arrangement-for-bosch-to-design-and-deliver-gmgs-graphene-aluminium-ion-battery-manufacturing-plant/Dec 2021Commencement coin cell battery development centrehttps://graphenemg.com/battery-pilot-plant/Dec 2021Initial coin cell batteries sent for customer feedbackhttps://graphenemg.com/graphene-aluminium-battery-customers-prototypes/Mar 2022Initial factory acceptance testing of semi-automated prototype battery cell assembly equipmenthttps://graphenemg.com/gmg-announces-initial-factory-acceptance-testing-of-semi-automated-prototype-battery-cell-assembly-equipment/Mar 2022Wood Engineering and GMG Sign a Letter of Intenthttps://graphenemg.com/gmg-and-wood-agree-collaboration-arrangement-for-wood-to-engineer-and-deliver-major-graphene-manufacturing-expansion-projects/May 2022Rio Tinto and GMG sign Letter of Intenthttps://graphenemg.com/gmg-riotinto-energysavings-battery/Jun 2022Commissioning of Pouch Cell Equipmenthttps://graphenemg.com/gmg-manufactures-first-pouch-cell/Jun 2022Bob Galyen, former chief technology officer of CATL, joins GMG technical advisory committee.https://graphenemg.com/gmg-technical-advisory-committee-leadership-team-additions-and-cfo-change/Aug 2022Investment decision for Phase 1 modular Graphene Production Planthttps://graphenemg.com/gmg-announces-phase-1-expansion-project-to-graphene-manufacturing-facility-for-energy-saving-products-and-batteries/Oct 2022Significant battery performance, cell and graphene production improvementshttps://graphenemg.com/gmgs-battery-update-significant-battery-performance-cell-and-graphene-production-improvements/Dec 2022Investment of $600k Battery Development Centrehttps://graphenemg.com/gmg-invests-au-600000-to-accelerate-battery-pouch-cell-customer-testing-development-in-2023/Feb 2023Australian Government Approval (AICIS) for production and sale of batteries.https://graphenemg.com/gmg-receives-regulatory-approval-to-enable-significant-commercial-sales/May 2023Battery Joint Development Agreement with Rio Tinto signedhttps://graphenemg.com/gmg-announces-battery-joint-development-agreement-with-rio-tinto/May 2023Battery Technology Readiness Level (BRTL) 2-3 reachedhttps://graphenemg.com/gmg-announces-battery-team-and-related-updates/May 2023Decision to switch to develop Pouch Cells (instead of Coin Cells)https://graphenemg.com/gmg-announces-battery-team-and-related-updates/Jul 2023Bob Galyen former chief technology officer of CATL joins GMG board of Directorshttps://graphenemg.com/graphene-manufacturing-group-appoints-former-chief-technology-officer-of-catl-limited-to-its-board-of-directors/Sep 2023Battery Pouch Cell Prototypes Multilayered Auto-Stacker Demonstrationhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-pouch-cell-prototypes-multilayered-auto-stacker-demonstration/Sep 2023Reaching 500 mAh capacity batteryhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Sep 2023Battery Technology Readiness Level (BRTL) 4 reachedhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Nov 2023Rio Tinto and GMG Partnership Video Launchedhttps://graphenemg.com/rio-tinto-gmg-battery-partnership-video-launch/Dec 2023Commissioning of modular Graphene Production Planthttps://graphenemg.com/graphene-manufacturing-group-commissions-modular-graphene-production-plant/Feb 20241000 mAh Capacity Reachedhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-1000-mah-capacity-reached-and-next-steps-toward-commercialisation/Mar 2024Graphene Manufacturing Group Secures AU$2 million Funding Grant from Queensland Government for Battery Pilot Planthttps://graphenemg.com/graphene-manufacturing-group-secures-au2-million-funding-grant-from-queensland-government-for-battery-pilot-plant/Aug 2024GMG's Graphene Aluminium-Ion Battery: Progress Update and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-progress-update-and-next-steps-toward-commercialisation/Mar 2025GMG's Graphene Aluminium-Ion Battery: Collaboration with World Leading USA Battery Innovation Centre and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-collaboration-with-world-leading-usa-battery-innovation-centre-and-next-steps-toward-commercialisation/ About BIC:BIC is a collaborative initiative designed to incorporate leadership from renowned universities, government agencies, and commercial enterprises. BIC is a public-private partnership and a not-for-profit organization focusing on the rapid development, testing and commercialization of safe, reliable and lightweight energy storage systems for defense and commercial customers. BIC is a unique organization that has been leading battery cell development for world leading battery companies for over 10 years and has carried out over 500 battery development projects.About GMGGMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041www.graphenemg.comNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the lower cost to produce GMG G+AI batteries, expectations for GMG G+AI batteries in respect of charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system when development is completed, that the new hybrid electrolyte is chloride free and non-corrosive, that the cathode and anode technology employed enables very fast and stable charging, that GMG G+AI batteries provide significant cost and weight savings relative to copper, that G+AI batteries can achieve over 150 Wh/kg charged over 1 hour and 75 Wh/kg when charged over 6 minutes following further development of cathode, anode, electrolyte and component weights, that G+AI batteries will progress to BTRL 7 and 8, that the timeline for the battery cell roadmap is achievable, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and which offers weight, cost and complexity advantages to a metal case and increased energy density, expectations for the lack of a thermal management system or fireproofing precautions, expectations for material and manufacturing costs, expectations for sales of LTO batteries, expectations for G+AI batteries being substitutable for LTO batteries at lower cost, expectations that G+AI batteries are viable 12V starter battery replacements and the rationale therefor and the advantages of pouch design for aerospace weight requirements and constrained dashboards of autonomous robots.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions that GMG G+AI batteries can be produced at lower cost, as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries, the speed and stability of charging, that G+AI batteries will progress to BTRL 7 and 8, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and offer weight, cost and complexity advantages to a metal case and increased energy density, that the service agreement with the BIC will enable the Company to optimize its cell design and battery manufacturing equipment, and that the Company will be able to meet its overall timeline on the battery cell roadmap. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that GMG G+AI batteries cannot be produced at lower cost, or any of the assumptions as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries can not be achieved, G+AI batteries do not offer expected speed and stability of charging, that G+AI batteries will not progress to BTRL 7 and 8, that a range of global companies in a variety of industries will not be interested in working with GMG, that the battery pack design will not be plastic and not offer weight, cost and complexity advantages to a metal case and increased energy density, that the Company will not be able to optimize the electrochemical behaviour of the pouch cell through laboratory experimentation or at all, that the Company will not be able to meet its overall timeline on the battery cell roadmap, that the service agreement with the BIC will not enable the Company to optimize its cell design and battery manufacturing equipment and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 04, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.[1] Lithium Titanate Oxide Battery Market Size, Share & 2030 Growth Trends Report[2] LFP: https://www.evlithium.com/catl-battery-cell/catl-150ah-lifepo4-battery-cell.htmlLNMC: https://keheng-battery.com/product/catl-nmc-3-7v-151ah-high-energy-density-battery-for-ev/LTO: https://www.global.toshiba/ww/products-solutions/battery/scib/product-next/product/cell/high-power.htmlLead Acid: https://www.altronics.com.au/p/s4530-12v-3.5ah-sealed-lead-acid-sla-battery/?srsltid=AfmBOoqZGMEIsX__YYOuRLC3nvYDFtNkf35qZYuYeoh3ACf4wrrOLISD[3] https://findingspress.org/article/21459-impact-of-charging-rates-on-electric-vehicle-batt[4] High-power type cells | SCiB™ Rechargeable battery | Toshiba[5] https://www.ritarpower.com/industry_information/The-Price-of-50-kWh-Lithium-Ion-Batteries-A-Comprehensive-Analysis_297.html#:~:text=Lithium%20Titanate%20(LTO)%20Batteries%3A,cost%20between%20%2440%2C000%20and%20%2460%2C000.[6] https://www.grepow.com/blog/battery-energy-density.html[7] Lithium Titanate Oxide Battery Market Size, Share & 2030 Growth Trends ReportTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/278044 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China ACN Newswire

CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China

SHENZHEN, Dec 15, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has obtained the relevant licensing rights to the innovative oral JAK1 inhibitor povorcitinib (proposed English generic name: Povorcitinib Phosphate Tablets) (“povorcitinib” or the “Product”), which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”), with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product.Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo, moderate to severe hidradenitis suppurativa (HS) and prurigo nodularis in several countries outside China. A Phase 2 clinical trial for the treatment of asthma is also ongoing.In March 2023, Incyte announced that povorcitinib met the primary endpoint in a global multi-center Phase 2b clinical trial for non-segmental vitiligo. Results showed that after 24 weeks of treatment, compared with vehicle, total body repigmentation of patients treated with povorcitinib once daily was significantly improved. Furthermore, according to the extended Phase 2b trial, longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation with a favorable tolerability profile[1]. In August 2025, Dermavon received the drug clinical trial approval notice issued by NMPA to conduct clinical trials of povorcitinib for the treatment of non-segmental vitiligo and other indications. Dermavon has initiated the clinical development of the Product in China and may consider further initiating clinical development of povorcitinib in China for the treatment of skin-related diseases such as HS and prurigo nodularis in the future.Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[2]. Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo. If approved in China, povorcitinib could provide a differentiated treatment option for patients with non-segmental vitiligo.The Product's inclusion in the list of Breakthrough Therapeutic Drugs is expected to accelerate its development and review process in mainland China. If approved for marketing in China, the Product has the potential to synergize with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) and the innovative drug currently under New Drug Application (NDA) review ruxolitinib phosphate cream, helping the product to quickly realize its clinical and commercial value and benefit more patients with skin diseases. Furthermore, if approved, the Product, together with topical ruxolitinib phosphate cream, will provide vitiligo patients with differentiated and comprehensive treatment options.The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to the Group (excluding Dermavon and its subsidiaries).About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. Results from a global multi-center Phase 2b clinical trial of the product for non-segmental vitiligo indication can be found on the Incyte official website: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-data-phase-2b-study-evaluating-povorcitinib2. Datas are from the China Insights Consultancy (CIC) reportCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
NEC Provides Vehicle Management Equipment for Autonomous Driving at Tokyo International Airport ACN Newswire

NEC Provides Vehicle Management Equipment for Autonomous Driving at Tokyo International Airport

TOKYO, Dec 15, 2025 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701) is providing vehicle management equipment (VME) for autonomous vehicles in an airport restricted area of Tokyo International Airport (Haneda Airport), one of the world’s busiest airports. This equipment is part of an order placed by the East Japan Civil Aviation Bureau of the Ministry of Land, Infrastructure, Transport and Tourism (MLIT).The VME includes signal equipment that synchronizes with autonomous vehicles and camera systems which help to cover blind spots. Use of towing tractors with a level 4 of autonomous driving ability* began in an airport restricted area of Haneda Airport in December. These tractors will be managed by Japan’s two largest airlines, ALL NIPPON AIRWAYS CO., LTD. and Japan Airlines Co., Ltd.With air traffic on the rise in recent years, airports have placed increasing urgency on labor-saving initiatives and efficiency improvements, particularly in ground operations. Against this backdrop, the MLIT, airlines, and airport operators are collaborating to promote the automation of towing tractors and buses used for passengers and crew transport. However, airports operate in a significantly different environment compared to public roads. Achieving autonomous operation requires extensive optimization across both technical and environmental aspects. Specifically, unique operating rules for runways, taxiways, and aprons need to be established, along with vehicle control systems that function in environments where aircraft and vehicles coexist. Furthermore, while safe traffic has traditionally relied on communication between human drivers, autonomous vehicles require new communication methods to ensure safety when they operate alongside human-driven vehicles.NEC’s VME enable autonomous driving by leveraging over half a century of experience in air traffic control and airport-related systems, as well as close collaboration with stakeholders that include airlines and autonomous vehicle manufacturers.The introduction of VME also enables automatic signal control at intersections within airport restricted areas. This facilitates safe and smooth traffic management among both human drivers and autonomous vehicles. Additionally, cameras placed in low-visibility areas send video to autonomous vehicle operators, helping to cover blind spots and support precise safety management.Going forward, NEC will continue to leverage digital technologies to help build a next-generation mobility society, striving to create safe, secure, and efficient transportation infrastructure.*Level 4 Autonomous Driving: Driving operations are automated by a system under specific conditions, eliminating the need for driver intervention. These specific conditions are based on factors such as the area in which a vehicle can be driven, weather, and speed.ShareAbout NECThe NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group’s approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society.For more information, please visit https://www.nec.com, Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
NEC and AEROTHAI Elevate Air Traffic Safety with Advanced Time Sync Solutions from Adtran Oscilloquartz ACN Newswire

NEC and AEROTHAI Elevate Air Traffic Safety with Advanced Time Sync Solutions from Adtran Oscilloquartz

TOKYO, Dec 15, 2025 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701), a leading global IT and network transformation services provider, and Aeronautical Radio of Thailand Ltd. (AEROTHAI), Thailand’s state enterprise for air traffic control and aeronautical communication, have partnered to capitalize on Adtran’s Oscilloquartz OSA 5412 timing solution. This deployment strengthens AEROTHAI’s air traffic management infrastructure by enhancing synchronization accuracy, mitigating Global Navigation Satellite Systems (GNSS)-related risks, and ensuring uninterrupted operations across critical airport systems.AEROTHAI is committed to delivering world-class navigation services that ensure safety, efficiency, and global competitiveness. As the organization faces rising air traffic demand, airspace congestion, and the challenge of modernizing aging infrastructure, AEROTHAI sought a solution that delivers greater accuracy, scalability, and reliability in order to replace outdated systems.To address these challenges, NEC has supplied AEROTHAI with Adtran’s Oscilloquartz OSA 5412, an advanced timing solution designed for precision and reliability, which improves timing accuracy, strengthens network resilience, and ensures compliance with international aviation standards—delivering a cost-effective, future-ready platform for safer skies.This deployment enhances aviation safety and reinforces Thailand’s role as a leading regional hub. By modernizing critical infrastructure, NEC helps AEROTHAI build long-term resilience and operational excellence. NEC remains committed to delivering secure, scalable network solutions that drive innovation and ensure a safer, more connected future for the aviation industry."Safe, efficient air traffic operations depend on timing that’s accurate, stable and secure, making synchronization the backbone of modern air traffic management. Our OSA 5412 provides AEROTHAI with scalable multi-source synchronization that minimizes GNSS exposure and streamlines operations. With integrated assurance and aviation‑grade safeguards, the solution supports uninterrupted service as traffic grows, giving controllers consistent, dependable timing. This deployment helps Thailand modernize critical infrastructure with technology that strengthens safety, improves efficiency and sets a clear path for expansion," said Stuart Broome, GM of EMEA and APAC sales, Adtran."We are proud to support AEROTHAI’s mission of delivering world-class air navigation services that meet user requirements for safety, standards, and efficiency. Through our strong global partnership with Adtran, we provide advanced timing solutions that enhance safety and efficiency for the airports in Thailand. NEC remains committed to delivering innovative, secure, and scalable solutions and services that empower the aviation industry for a safer, more connected future worldwide," said Masayuki Kayahara, Corporate SVP, Global Network Division, NEC Corporation.About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com or NEC’s Network Solutions at https://www.nec.com/en/global/solutions/5g/index.html. Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
Indonesia’s KAI Launches Farmer-Trader Train, Expands Facial Recognition Tech Ahead of 2025/2026 Holiday Travel Surge ACN Newswire

Indonesia’s KAI Launches Farmer-Trader Train, Expands Facial Recognition Tech Ahead of 2025/2026 Holiday Travel Surge

JAKARTA, Dec 15, 2025 - (ACN Newswire via SeaPRwire.com) - Indonesia's state-owned railway operator PT Kereta Api Indonesia (KAI) has rolled out two major initiatives aimed at strengthening national mobility and accelerating its digital shift: the launch of the Farmer and Trader Train on the Merak Commuter Line, and the expansion of face recognition boarding technology ahead of the 2025/2026 Christmas and New Year travel season.Farmer-Trader train to facilitate the movement of agricultural goods, processed food, and small-scale merchandise by providing dedicated cargo space within a commuter railway environment.KAI said the programs reflect its commitment to inclusive transport services while enhancing operational efficiency and environmental performance — moves that align with international railway modernization trends.A special passenger train featuring oversized windows and often a large glass roof (sunroof) to provide unobstructed, wide-angle views of the passing scenery, turning the journey itself into a scenic experience."KAI is committed to building a rail ecosystem that supports grassroots economies while adopting technologies that meet global service standards," said KAI President Director Bobby Rasyidin. "These initiatives reinforce railways as an inclusive, efficient, and sustainable mode of public transport."New Farmer–Trader Train Strengthens Local Product DistributionEffective 1 December 2025, KAI began operating the Farmer and Trader Train on the Merak–Rangkasbitung corridor in Banten Province. The service is designed to facilitate the movement of agricultural goods, processed food, and small-scale merchandise by providing dedicated cargo space within a commuter railway environment.The rolling stock was fully redesigned by Balai Yasa Surabaya Gubeng, KAI's technical workshop, which modified the interior layout, baggage sections, loading–unloading access points, and safety signage to meet the needs of micro and small enterprises."The train has been engineered by our in-house experts to ensure safe, orderly, and convenient goods movement without disrupting passenger flow," continued Rasyidin.The service operates under a government-funded Public Service Obligation (PSO) scheme with a flat fare of Rp3,000, allowing up to two cargo units per user. It is attached to 14 daily Commuter Line services and stops at 11 stations across coastal and agricultural areas.On launch day, 95 customers used the service, carrying agricultural produce, snacks, and handicrafts for markets in Serang, Cilegon, and Merak. KAI expects the service to reduce traders' reliance on road-based logistics and shift more local supply chains onto rail.Rasyidin said the initiative strengthens regional economic resilience: "Reliable logistics access for small producers is fundamental to local economies. This service opens a more predictable distribution channel for farmers and traders."Facial Recognition Technology Boosts Efficiency, Cuts WasteKAI is also expanding its facial recognition boarding system to improve passenger processing and reduce paper usage in major stations.KAI VP Public Relations Anne Purba, explains, between January and October 2025, the feature recorded 9.29 million uses, cutting ticket paper consumption by 23,245 rolls, equivalent to Rp341 million in savings. Since the system debuted in 2023, it has been used by 19.4 million passengers, contributing significantly to KAI's environmental and cost-reduction goals."Facial recognition shortens boarding time and significantly reduces paper waste, supporting more environmentally responsible operations," Purba said.The technology is now available in 22 stations, with wider deployment planned ahead of peak holiday travel to reduce queues and streamline passenger flow.Purba underscored the strategic value of automation: "Digitalization is not just innovation—it is increasingly essential to managing national mobility at scale. This system helps maintain operational stability when travel demand peaks."Holiday Ticket Sales Climb, Discounts ExpandedDemand for the year-end holiday period—18 December 2025 to 4 January 2026—continues to rise. As of 26 November, KAI had sold 629,060 tickets, or 21.15% of the roughly 3 million seats available.To support affordability and smooth travel, KAI is offering 30% discounts for 156 regular services and 26 additional economy-class trains, totaling 1.5 million discounted seats valid from 22 December to 10 January.Purba said higher mobility is expected across Java and Sumatra: "We are preparing large capacity and fare incentives to ensure safe, orderly, and accessible travel throughout the holiday season."Inclusive and Technology-Driven Mobility for IndonesiaBy combining inclusive rural-focused services with large-scale digital transformation, KAI aims to bring Indonesia's rail sector closer to global standards of accessibility, efficiency, and sustainability."Our strategy aligns with international efforts to build modern public transport systems that deliver broad social and economic impact," Purba concluded.For More Information, please contact:Anne PurbaVP Public RelationsPT Kereta Api Indonesia (Persero)Source: PT Kereta Api Indonesia (Persero), https://www.kai.id Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
TransNusa Secures 19 Scheduled Flight Routes Within Three Years of Operations ACN Newswire

TransNusa Secures 19 Scheduled Flight Routes Within Three Years of Operations

TransNusa Launched 11 International Routes in 3 YearsIndonesia-based PT TransNusa Mandiri Aviation grows a strong brand with expansion focusing on international routesTransNusa focuses on international tourism island destinations to offer domestic and foreign tourists increased air connectivityTransNusa introduces four new domestic scheduled direct flights to boost connectivity from Bali to Lombok and Bima as well as between renowned diving destinations Manado to Sorong and Sorong to Timika, world’s largest gold mining islandJAKARTA, Dec 15, 2025 - (ACN Newswire via SeaPRwire.com) - TransNusa has successfully launched four new domestic routes today, securing 19 routes in total within three years of operations.TransNusa Group CEO, aviation veteran, Datuk Bernard Francis, known for his acute, unique and out-of-the-box turnaround and change management strategies, led TransNusa towards a secure yet bold growth pattern using a customized business model, which was specifically developed to suit the changing market demand after the onslaught of the pandemic.“What we envisioned for TransNusa was to build an Indonesian-based airline with strong fundamentals. Today, thanks to our hard working and diligent team, the TransNusa brand has grown to resonates confidence and trust,” said Datuk Bernard, adding that TransNusa’s shareholder, China Aircraft Leasing Group Holdings Limited (CALC) and business partners also played a large role in helping build TransNusa into the strong brand it is today.Within 6 months of its operations, TransNusa launched its first international route between Jakarta and Kuala Lumpur, followed by three additional international routes in that same year, including Singapore and China.TransNusa also implemented a milestones as well as initiated and developed new domestic routes, such as the Bali-Manado route.In addition, TransNusa the first Indonesian airline to operate regular scheduled international flights into Guanzhou from three destinations in Indonesia.Datuk Bernard said the primary factor in the successful growth of TransNusa, in the last three years, was their goal to implement a lasting and impactful change around not just the organisation and its people but also its business model and operations.“In TransNusa, a 100% change is not possible overnight, whereas a 5% change in a moderate manner is not only more feasible but allows for a lasting change,” said Datuk Bernard, explaining that it was that principal which has been the backbone of TransNusa's operations and growth.On the new domestic route launches, Datuk Bernard said that TransNusa hopes to provide increased connectivity and travelling options to domestic and international tourists.“We would like to play our part in boosting and increasing air connectivity within Indonesia’s internationally renowned tourism island destinations.“Our focus is in increasing direct flight to destinations that are world renowned for its unique and stunning landscape and natural offerings,” said Datuk Bernard.DATUK BERNARD FRANCIS… TransNusa's team and business partners contributed to the growth of the airline and it’s brand.Flight DetailsTransNusa’s flight from Bali to Lombok will operate two times daily beginning Monday, December 15. The TransNusa flight will depart Bali from the Denpasar International Airport at 07.30am and arrive in Lombok International Airport at 07.55am, with the return flight departing Lombok at 08.25am and arriving in Bali at 09.05am. The second TransNusa flight will depart Bali at 15.55pm and arrive in Lombok at 16.50pm, with the return flight departing Lombok at 17.20pm and arriving in Bali at 18.05pm.“We will increase the frequency of the scheduled flights for the Bali-Lombok route to three times daily on December 21.” Said Datuk Bernard.The third scheduled flight will depart Bali at 18.55pm and arrive at Lombok at 19.35pm. The scheduled flight from Lombok will depart at 20.00pm and arrive in Bali at 20.25pm.Meanwhile, TransNusa’s flight from Bali to Bima will also begin on Monday, December 15.“For the first week, we will operate one scheduled flight from Bali to Bima on Monday, Wednesday, Friday and Sunday.“Starting December 22, TransNusa will operate daily scheduled flights from Bali to Bima,” said Datuk Bernard, adding that the flight will depart Bali from the Denpasar International Airport at 09.35am and arrive at 10.35am at the Sultan Muhammad Salahuddin Airport in Bima.The return flight will depart Bima’s Sultan Muhammad Salahuddin Airport at 11.00am and arrive at Bali’s Denpasar International Airport at 12.10pm.Meanwhile, TransNusa’s schedule flight from Sorong to Timika will operate four times weekly on Monday, Tuesday, Thursday and Saturday.The flight, which will also begin on December 15, will depart Sorong from the Domine Eduard Osok International Airport at 10.50am and arrive in Timika’s Mozes Kilangin Airport at 12.10pm. The return flight will depart Timika at 12.40pm and arrive in Sorong at 14.00pm.On the much sought-after Manado-Sorong route, Datuk Bernard said that TransNusa’s will operate its scheduled flight from Manado to Sorong four times weekly.The scheduled flight from diving haven Manado will operate on Monday, Tuesday, Thursday and Saturday. The flight will depart Manado’s Sam Ratulangi International AIrport at 08.00am and arrive in Sorong’s Domine Eduard Osok International Airport at 10.20am. The return flight will depart Sorong at 14.30pm and arrive in Manado at 14.50pm.TransNusa, A Short HistoryThe 3-year old TransNusa, led by aviation expert and veteran, Datuk Bernard, made waves in the aviation industry with its unique domestic and international business development and growth strategy.Within just 6 months of operations, in 2023, the airline, known then as a new player with new rules, launched its first international route between Jakarta and Kuala Lumpur, followed by the launch of scheduled flights between Jakarta and Singapore.TransNusa, which established itself as a Premium Service Carrier, made headlines in Malaysia, Singapore, China and around the world with news of being the first airline in Indonesia to introduce new exciting routes. In 2023, during its first year of operations, TransNusa became the second Indonesian airline to receive approval to fly to China. In 2024, TransNusa became the first in the world to develop and introduce a new domestic route connecting Bali and Manado. In October 2025, TransNusa added yet another milestones by becoming the first Indonesian airline and second airline in the world to launch scheduled flights from Manado to Guangzhou, China.Media Contact:Trina Thomas RajMobile: +6012 4992672E-mail: trina@myqaseh.org Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership ACN Newswire

Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership

TOKYO and WESTBOROUGH, Mass., Dec 15, 2025 - (JCN Newswire via SeaPRwire.com) - Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer, and more fulfilling, has announced an additional commitment to its corporate venture capital fund, Olympus Innovation Ventures, LLC (OIV), with the launch of Olympus Innovation Ventures Fund II. Building on the success of the initial fund, Olympus will deploy $150 million to invest in promising MedTech startup companies focused on Gastrointestinal (GI), Urology and Respiratory.Abigail Hunter-Syed, Head of OIV, speaking at The MedTech Conference 2025(photo courtesy of MedTech Innovator)OIV, a wholly owned subsidiary of Olympus Corporation of the Americas, aims to generate a robust pipeline of M&A opportunities, partnerships, and valuable market insights. OIV is stage-agnostic, prioritizing early to growth-stage companies globally with therapeutic solutions for targeted medical specialties. In addition to capital, Olympus will continue to help its portfolio companies succeed by contributing its clinical and technical expertise, access to healthcare professionals and hospitals, and ability to launch and scale innovative solutions in the global market.OIV focuses on investments in passionate founders who are revolutionizing medical solutions. The fund invests in customer-driven solutions in medical devices, diagnostics and digital health. Since its inception in October 2021, OIV has made nine investments in areas such as AI workflow solutions and medical imaging agents for cancer detection.Bob White, Director, Representative Executive Officer, President and Chief Executive Officer at Olympus, said, “Our expanded venture fund commitment reflects Olympus’ deep dedication to innovation and growth. By supporting visionary innovators and breakthrough technologies over time, we aim to accelerate solutions that improve patient outcomes and strengthen our leadership in MedTech.”Cerity Partners Ventures (Cerity), a firm specializing in corporate venture capital, will continue to help manage the Olympus venture fund. Cerity will work closely with senior executives of Olympus in all aspects of operating the fund."The Cerity Partners Ventures team is excited to continue working with Olympus, leveraging our collective technical strengths, industry relationships, and subject matter expertise to fund and support leading entrepreneurs,” noted Kindra Tatarsky, Partner at Cerity Partners Ventures. “This fund will build on Olympus Innovation Ventures’ mission to be the partner of choice for innovators, creating a competitive advantage for their startups."Gabriela Kaynor, Executive Officer and Chief Strategy Officer at Olympus and Chair of the OIV Investment Committee, said, “With an additional commitment to corporate venture capital, we will continue to make investments in startup teams who are building unique solutions in endoscopy-enabled care. Olympus Innovation Ventures investments help accelerate our progress toward developing the endosuite of the future with capabilities for early detection, diagnosis, and advanced therapies powered by AI, robotics, and beyond.”Olympus remains committed to strengthening its market leadership through innovation, strategic partnerships, and investment in breakthrough technologies. Moving forward, OIV will continue to support Olympus’ commitment to elevating unique capabilities and drive growth in the global MedTech ecosystem.For more information, please visit: olympusamerica.com/olympus-innovation-ventures or email: ventures@olympus.com.About Cerity Partners VenturesCerity Partners Ventures partners with corporations to help launch and manage their venture capital programs. CPV works closely with each corporation to achieve the financial and strategic benefits from venture capital investments. The firm is a Registered Investment Adviser and maintains offices in Los Angeles, Philadelphia, and San Francisco. More information on CPV can be found at https://ceritypartners.com/corporations/corporate-venture-capital/About OlympusAt Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global LinkedIn accounts.Media contact:Mail: Global-Public_Relations@olympus.comOlympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
Honda to Launch New Heritage Service Business ACN Newswire

Honda to Launch New Heritage Service Business

TOKYO, Japan, Dec 12, 2025 - (JCN Newswire via SeaPRwire.com) - Honda Motor Co., Ltd. today announced plans to launch Honda Heritage Works, a new heritage service business for classic Honda (and Acura) sport-type models, on April 1, 2026. For customers who cherish and wish to continue driving their beloved vehicles for many years, Honda will offer reproduction parts on a global basis to replace discontinued parts, as well as a restoration service in Japan.Honda Heritage Works will consist of two services: Honda Heritage Parts, which reproduces and supplies certain discontinued genuine parts no longer in mass production, and Honda Restoration Service, a new service to be offered in Japan to restore customer vehicles utilizing the reproduced parts. Both will start with the first-generation NSX, with plans to expand to other classic sport-type models in the future.Ahead of the service launch in April 2026, Honda today launched the official Honda Heritage Works website. Detailed information, including pricing and service offerings, will be released sequentially leading up to the start of the service.Official Honda Heritage Works website URL:https://www.honda.co.jp/heritage-works/ (Japanese)Overview of Honda Heritage WorksHonda Heritage PartsTo date, Honda has continued to supply genuine service parts for a certain time period after the discontinuation of the production of its models. However, it has become increasingly difficult to supply many of the parts to support classic models.To address this challenge, Honda will offer both “Genuine Honda Heritage Compatible Parts” and “Genuine Honda Heritage Reproduction Parts” under the lineup of Honda Heritage Parts.- “Genuine Honda Heritage Compatible Parts” are newly redeveloped and reproduced to replace original parts no longer available for sale by Honda. This was made possible by the establishment of a new collaborative framework with parts suppliers, technological advancements, and adoption of new materials and manufacturing methods.- “Genuine Honda Heritage Reproduction Parts” will be reproduced using the same materials and production methods that were used for the original parts.Both types of parts will be available globally in the Honda Heritage Parts lineup. A list of available Honda Heritage Parts will be posted on the official Honda Heritage Works website and updated as new parts are added.Honda Heritage Parts will be also available globally for purchase through same distribution channels as other standard Honda genuine parts in each country.Two types of Honda Heritage Parts with different reproduction methodsHonda Restoration ServiceBased on the concept of “thorough pursuit of original driving feel created by Honda at the time,” since 1993, Honda has been offering restoration services for the first-generation NSX under the name of the “NSX Refresh Plan.” This service will be renewed as Honda Restoration Service, which will use Honda Heritage Parts to restore the vehicle’s original performance, look and feel as faithfully as possible.In conjunction with the launch of this service, a Honda facility in Takanezawa, Tochigi Prefecture, Japan - the birthplace of the first-generation NSX and the facility where the NSX Refresh Plan has been operating - will be renamed from Refresh Center to Honda Heritage Works Takanezawa. The facility will offer authentic and comprehensive restoration works that only Honda can achieve.The service menu consists of two options:- Basic Restoration packages frequently requested works on performance-related items such as the engine and suspensions.- Total Restoration also includes exterior and interior works as well as more detailed, comprehensive works tailored to the condition of each vehicle.Starting in early January 2026, applications for restoration works for the first-generation NSX (NA1-100) will be accepted through Honda Cars dealerships throughout Japan, with works scheduled to begin in April.More details, including the application process and pricing, will be posted on the official Honda Heritage Works website in early January 2026.Please note: the application period for the NSX Refresh Plan ended at the end of August 2025.Honda Restoration Service menuRestoration worksBasicRestorationTotalRestorationRemoval of the engine from the vehicle for parts replacement,cleaning, and internal inspectionOOReplacement of suspension-related partsOOReplacement and adjustment of age-worn parts related to doorsand other openingsOOExterior restoration(Complete repainting after disassembly to the body in white)OptionalOInterior restoration(Reupholstery of seats, dashboard, door panels, and controls)OptionalO With the launch of Honda Heritage Works, Honda will further enhance its after-sale services and deliver added value so that customers who have cherished and enjoyed classic Honda sport-type models for many years can continue to drive their beloved vehicles with great confidence. Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
Bank Mandiri Enhances Digital Resiliency for Financial Trading in Indonesia through Advanced Time Sync Solutions with NEC and Adtran Oscilloquartz ACN Newswire

Bank Mandiri Enhances Digital Resiliency for Financial Trading in Indonesia through Advanced Time Sync Solutions with NEC and Adtran Oscilloquartz

TOKYO, Dec 12, 2025 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701), a leader in the integration of IT and network technologies, today announced that Indonesia-based Bank Mandiri has selected NEC’s Network Transformation Service to implement Adtran’s innovative Oscilloquartz time synchronization technology in its Jakarta data centers, elevating the bank’s digital infrastructure. With this new secure timing solution, Bank Mandiri is reinforcing its abilities to comply with stringent global banking regulations, which enables effective auditing for fraud prevention and enhances operational efficiency.As one of the largest banks in Indonesia, Bank Mandiri aims to be the preferred financial partner for its customers by seamlessly integrating its financial products and services into their daily lives through the delivery of simple, fast digital banking solutions. While Bank Mandiri accelerates digital banking for social innovation, enhancing security to protect customers from fraud is crucial. However, using a traditional public Network Time Protocol (NTP) clock server has not been accurate enough to meet industry-standard regulations, such as MiFID, for effective fraud prevention. Moreover, reliance on public NTP servers may result in greater visibility of Bank Mandiri’s network, which creates a need for enhanced vigilance and risk management.To address these challenges, NEC collaborated with its global partner Adtran to deploy the OSA 5412, a versatile NTP clock server designed for precise time synchronization with upgradeability to support Precision Time Protocol (PTP). As dedicated NTP servers in data centers, OSA 5412 provide increased accuracy and reliability for important activities such as transaction reporting, effectively meeting banking regulations for traceability and enhanced customer security. Moreover, this solution offers advanced jamming and spoofing detection to safeguard against cyber threats.Bank Mandiri’s adoption of NEC’s Network Transformation Service and Adtran’s Oscilloquartz time synchronization technology positions the bank at the forefront of digital banking in Indonesia, setting a new benchmark for security and operational excellence. Moving forward, NEC is committed to supporting the evolving needs of the banking industry and driving the advancement of secure digital banking."Bank Mandiri remains dedicated to driving digital innovation that enhances both customer satisfaction and security. Through our collaboration with NEC and Adtran, we have transformed our time synchronization capabilities, ensuring greater transaction traceability and operational reliability. As a digital pioneer in Indonesia's banking sector, we will continue to lead with innovation—leveraging AI and cutting-edge digital technologies to deliver trusted, future-ready financial services for our customers."- Denny Dwi Mavianto – Team Leader Bank Mandiri"Precise and secure time synchronization is essential to building trust in digital banking. Our OSA 5412 platform delivers industry-leading accuracy, resiliency and advanced security features, such as jamming and spoofing detection. This deployment not only meets global regulatory standards but also strengthens Bank Mandiri’s foundation for secure, real-time financial services in today’s dynamic digital economy."- Stuart Broome, GM of EMEA and APAC sales at Adtran."We are honored to support Bank Mandiri in elevating its digital infrastructure through our advanced network transformation and time synchronization solutions, in partnership with Adtran. NEC has long been dedicated to driving digital innovation in the banking sector by modernizing critical infrastructure, and we remain committed to delivering new advancements. We look forward to empowering financial institutions like Bank Mandiri to drive innovation and achieve business success in the AI and digital era."- Masayuki Kayahara, Corporate SVP, Global Network Division, NEC CorporationAbout NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
NEC and ClimateAi sign a Memorandum of Understanding (MoU) for business co-creation to enhance climate resilience across various industries ACN Newswire

NEC and ClimateAi sign a Memorandum of Understanding (MoU) for business co-creation to enhance climate resilience across various industries

TOKYO, Dec 12, 2025 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701) and ClimateAi, Inc. have signed a Memorandum of Understanding (MoU) for the co-creation of business opportunities aimed at enhancing resilience against the impacts of climate change across multiple industries.By integrating ClimateAi's climate adaptation and risk forecasting technology with NEC's expertise in agritech, AI, data analysis, and optimization, the two companies aim to build solutions that directly support climate adaptation decision-making at the farm, corporate, financial, and governmental levels.BackgroundThe progression of climate change is heightening physical risks to food security and corporate supply chains, such as agricultural production variability, logistic disruptions, and price fluctuation risks.However, visualizing the return on investment (ROI) of climate adaptation measures—and continuously monitoring their effectiveness over time—remains challenging, making it difficult to mobilize funds and optimally take preventive measures.In August 2025, NEC and ClimateAi collaboratively developed a concept model to quantify the effectiveness of adaptation strategies like irrigation, varietal changes, and planting schedule adjustments using AI, specifically targeting cacao and rice in Africa. The model demonstrated its potential to support adaptation finance, policy formulation, and on-the-ground agricultural planning. This achievement was presented at TICAD9 (*1) and COP30, generating strong market interest from international organizations, development banks, and industry stakeholders.This MoU aims to promote the co-creation of comprehensive climate resilience solutions spanning agricultural sites, corporate supply chains, finance, and insurance, with a view towards transitioning from the demonstration stage to commercial application.Areas of collaboration- Both parties agreed to collaborate on business development in the following areas:1. Analysis of the ROI for climate change adaptation measures in the agricultural sectorBy combining ClimateAi's long-term climate change prediction technology with NEC's expertise in the agritech business, the companies aim to develop a service that analyzes yield, risk exposure, and the investment effectiveness of climate adaptation measures, such as crop changes and irrigation facility introductions.Considering the varying impacts of climate change on different lands, the goal is to analyze optimal adaptation measures from an economic perspective and support the advancement of agricultural assistance by international organizations, development banks, and governments.2. Enhancing supply chain resilience from the viewpoint of climate change adaptationTargeting the downstream agricultural sector, namely manufacturing industries that use agricultural products as main raw materials (such as food and beverage manufacturing), NEC and ClimateAi aim to support supplier optimization and improve resilience across upstream farms and supply networks to achieve services that support industrial adaptation to climate change.This technology can also support supply chain and procurement planning decisions across any industrial supply chain.3. Digital solutions for other sectors, including financial services and insuranceThe companies will explore the enhancement of financial services needed for climate adaptation-such as agricultural insurance-and identify new use cases for climate adaptation data across additional industries.Comments from each companyNaohisa Matsuda, Senior Director, Future value co-creation department / Business innovation division, NEC"NEC is delighted to announce an agreement on business development in collaboration with ClimateAi. By combining ClimateAi's strength in climate risk prediction and analysis with NEC's AI and data utilization capabilities and societal implementation prowess, we are confident that we can contribute to enhancing the resilience of supply chains and infrastructure while promoting climate change adaptation."Under the philosophy of ‘NEC Open Innovation,’ we are advancing the creation of new social value with diverse partners.Moving forward, through our collaboration with ClimateAi, we aim to accelerate implementation both domestically and internationally, centering on visualizing the impacts of climate change and advancing decision-making to co-create a sustainable society."Himanshu Gupta - CEO, ClimateAi"NEC’s global network and field partnerships open the door to implementing climate adaptation where it’s needed most. We’re energized by the work ahead—supporting organizations with agricultural planning, strengthening supply-chain resilience, and building practical solutions that can be deployed quickly and at scale. This collaboration also enables us to bring climate-informed insights into supply-chain and procurement planning, helping industries make better decisions as climate pressures grow."Future prospectsUnder the MoU, both companies will define priority regions, crops, and customer segments, and strengthen collaboration with international organizations, development banks, local partners, food manufacturers, trading companies, and financial and insurance institutions to advance early commercialization.NEC and ClimateAi aim to contribute to sustainable agriculture, food security, and greater industrial resilience.NEC’s new business development, under the key message "The future is ours to shape," is advancing NEC Open Innovation (*3) through diverse co-creation with a wide range of startups and partner companies. NEC’s collaboration with ClimateAi is one such initiative. By uniting innovative technologies with cross-domain collaboration, NEC continues to create new social value and shape the future.(*1) NEC to participate in "TICAD Business Expo and Conference" and thematic events for TICAD 9https://www.nec.com/en/press/202508/global_20250805_03.html(*2) NEC Lectures on "Strengthening Supply Chain Resilience through Digital Technologies" at COP30 Seminar Hosted by the Ministry of the Environment (Press Release in Japanese) https://prtimes.jp/main/html/rd/p/000001139.000078149.html(*3)https://www.nec.com/en/global/innovation/index.htmlAbout ClimateAi, Inc.ClimateAi is a climate adaptation and resilience platform purpose-built for the agriculture, food, and consumer goods sectors. It combines AI-powered weather modeling with phenological and water-scarcity data to deliver highly localized, crop-specific agricultural impact insights across the short, medium, and long term. With deep expertise in climate–agriculture interactions and a client base that spans agricultural and consumer-goods multinationals as well as agricultural investors, ClimateAi turns complex climate data into actionable insights. For more information, visit ClimateAi at https://www.climate.ai.About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten ACN Newswire

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

HONG KONG, December 12, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (“Everest Medicines China”), has entered into two strategic agreements with privately held Hasten Biopharmaceutical Co., Ltd. (“Hasten”). The first is a Commercialization Services Agreement leveraging Everest's existing sales and marketing organization to provide commercialization services for a portfolio of Hasten's mature assets.The second is a License Agreement granting Everest the exclusive license to develop, register and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor, which is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) in Greater China.The two agreements are expected to create significant financial and strategic synergies, enhancing the operational efficiency of Everest’s existing commercial platform and accelerating the build-out of life-cycle and multi-channel commercialization capabilities. At the same time, they establish an attractive strategic footprint for the Company in the cardiovascular disease area. Through this collaboration, Everest will further strengthen its commercial foundation in China, expand market share, and inject core momentum into the long-term growth of its cardiovascular business. The potential approval of Lerodalcibep in Greater China in 2027 is expected to contribute to future revenue growth within Everest's cardiovascular portfolio.Commercialization Synergies to Strengthen Competitiveness Across a Multi-Product PortfolioEverest Medicines China will receive service fees from Hasten calculated by multiplying the net sales of each product for the applicable quarter by the applicable rate, which ranges from 20% to 55%. The proposed maximum annual caps for the transactions contemplated to be paid by Hasten for the three years ending December 31, 2028 are set at RMB 560 million in 2026, RMB 616 million in 2027, and RMB 677 million in 2028.The Commercialization Service Agreement covers six mature, commercially available products across three major therapeutic areas—critical care, cardiovascular disease, and metabolic disorders—including Rocephin(R), Stilamin(R), and Ebrantil(R) in critical care; Edarbi(R) and Blopress(R) in cardiovascular disease; and Basen(R) in metabolic disease. The portfolio is highly synergistic with Everest’s existing commercial infrastructure and strategic focus. Among them, the three core critical care products—Rocephin(R), Stilamin(R), and Ebrantil(R)—play an essential clinical role in the treatment of infectious, gastrointestinal emergency, and cardiovascular emergency conditions. Rocephin(R), for example, is a broad-spectrum, third-generation cephalosporin that has achieved coverage in more than 8,500 hospitals nationwide and holds over 80% market share, maintaining strong and sustained clinical demand in the treatment of complex infections. Notably, these transactions are expected to generate significant synergies for Everest by aligning XERAVA(R) with Hasten’s critical care portfolio — including Rocephin(R) and Stilamin(R) — across complementary geographic footprints, channel access and hospital coverage, while further strengthening the Company’s commercialization capabilities and life-cycle management of innovative medicines.With the addition of this product portfolio, the Company’s commercial presence in key therapeutic areas such as critical care and cardiovascular diseases will be further expanded, creating stronger synergies with its existing commercialization organization and providing more robust support for the scaled development and revenue growth of its commercial platform.Introduction of Lerodalcibep to Expand Strategic Footprint in Cardiovascular DiseasesThe agreement grants Everest the exclusive license to develop, register and commercialize Lerodalcibep in Greater China, together with a royalty-free, exclusive license to use Hasten's trademarks for the product in the territory. Pursuant to the license agreement, Everest Medicines China will make an initial payment of US$29 million (approximately RMB 205 million), and may pay up to US$30 million (RMB 212 million) in potential development and regulatory milestone payments and up to US$280 million (RMB1977 million) in potential sales milestones, in addition to royalties based on the total, aggregate annual net sales.Lerodalcibep, developed by privately-held and U.S.-based company LIB Therapeutics, is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lerodalcibep is a novel, small protein-binding, third-generation PCSK9 inhibitor, and has been developed as a more patient friendly and convenient, once-monthly, single small-volume, subcutaneous injection that will not require refrigeration at home or in travel. These features make Lerodalcibep a unique alternative to approved PCSK9 inhibitors. In large, global phase 3 clinical trials in over 2,500 patients, Lerodalcibep has demonstrated sustained LDL-C reductions of >60% in patients with, or at very-high or high risk of, cardiovascular disease (CVD) and >55% in those with heterozygous familial hypercholesterolemia (FH) who have more severe LDL-C elevations. In addition, the head-to-head LIBerate-VI study, comparing Lerodalcibep with Inclisiran, demonstrated the superiority of Lerodalcibep (p=0.0319). Lerodalcibep is expected to expand treatment options for the millions of patients around the world with CVD, including the 30 million individuals with FH. These LDL-C reductions have been confirmed in a recent phase 3 clinical trial in a Chinese population with, or at very high risk of, CVD including FH.Multiple PCSK9 inhibitors are currently approved and marketed in China, with a combined market size of approximately RMB 3 billion and year-over-year revenue growth of 95% in 2024. The market is expected to further increase to approximately RMB10 billion in 2030, according to a Frost & Sullivan report. Despite an estimated 400 million individuals in China with dyslipidemia, only ~14% receive lipid-lowering treatment, reflecting low penetration and significant unmet medical need. Lerodalcibep has patent exclusivity in China through 2039.Lerodalcibep is currently under regulatory review by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In Greater China, Biologics License Application (BLA) submission is expected in 1H 2026, with the potential for approval in 2027.Everest considers Lerodalcibep an important future growth driver and a key addition to its innovative medicines portfolio. The transaction is viewed as aligned with the Company’s strategy to focus on high-potential therapeutic areas and to expand its late-stage pipeline through business development collaborations, thereby strengthening its overall portfolio.Market commentators note that the two agreements provide both near-term revenue contribution and clear longer-term growth opportunities. By leveraging its established medical, market access, marketing and sales capabilities, Everest is expected to improve the efficiency of its commercial operations and resource utilization, while further demonstrating the scalability and resilience of its commercial platform. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Anime Tokyo Station: A Series of Linked Events to Be Held in Conjunction with the Anniversary Joint Exhibition ACN Newswire

Anime Tokyo Station: A Series of Linked Events to Be Held in Conjunction with the Anniversary Joint Exhibition

TOKYO, Dec 12, 2025 - (JCN Newswire via SeaPRwire.com) - Anime Tokyo Station, an exhibition center for Japanese anime operated by the Tokyo Metropolitan Government and the Association of Japanese Animations, has welcomed 240,384 visitors from Japan and overseas (as of November 30, 2025) as a facility that promotes the appeal of Japanese anime to the world under the motto “Making ANIME more interesting, Bringing ANIME far into the future.”We are pleased to announce that a variety of events will be held in conjunction with the ongoing “Digimon Adventure 02” & “Magical DoReMi #” ANIME 25TH ANNIVERSARY JOINT EXHIBITION.As part of the monthly “Anime Watch Party” held at Anime Tokyo Station, a special winter event will feature screenings of “Digimon Adventure 02” and “Magical DoReMi #.” An event screening the first episodes of both titles will take place on Sunday, December 21, 2025. To commemorate the occasion, a special guest may also make an appearance.In the Special Lecture Series “The Power to Create Anime: Nine Lessons for the Future,” where attendees can listen, learn, and gain insight into the anime industry through the words of leading professionals, Hiroyuki Kakudo, the series director of Digimon Adventure 02, will appear in Session 4, and Hiromi Seki, the producer of Magical DoReMi #, will appear in Session 5. This event offers a rare opportunity to hear valuable stories—including on-site experiences and behind-the-scenes episodes of anime production—at Anime Tokyo Station, a facility dedicated to sharing the appeal of anime.In addition, meet-and-greet events featuring characters from “Digimon Adventure 02” and “Magical DoReMi #” have been confirmed. On Sunday, January 25, 2026, Doremi-chan from Magical DoReMi # will make an appearance, and on Sunday, February 1, 2026, Veemon from Digimon Adventure 02 will appear. Why not enjoy the exhibitions while also taking commemorative photos to capture your memories?The latest updates on each event are available on the official website and social media accounts. We invite you to experience the world of Digimon Adventure 02 and Magical DoReMi # here at Anime Tokyo Station, a facility dedicated to sharing the appeal of anime.“Anime Watch Party 12” – Winter Special Event Details“Anime Watch Party 12” – Winter Special Event(1) Date and time: Sunday, December 21, 20251. 13:00–14:25 Magical DoReMi # — Talk & Giveaway Quiz Contest2. 15:00–16:00 Digimon Adventure 02 — Talk & Giveaway Quiz Contest3. 16:30–17:00 Magical DoReMi #4. 17:30–18:00 Digimon Adventure 02A special guest may also make an appearance on the day.For the latest updates, please check the official website, social media accounts, and in-facility announcements.*Noriko Namiki will be present at (1) and (2).*Anime screening only at (3) and (4).(2) Venue: 1st Floor (in front of Interactive Vision), Anime Tokyo Station (Tokyu East 5, 2-25-5 Minami-Ikebukuro, Toshima City, Tokyo)(3) Films to be screened"Digimon Adventure 02" – Episode 1: The Inheritor of CourageStory summaryThe Digimon Kaiser suddenly appears in the once-peaceful Digital World, bringing suffering to Agumon and the others. Taichi heads to the Digital World to save them, but he finds himself in danger when the Kaiser’s power prevents Agumon from evolving. Upon learning that Taichi is in trouble, Takeru and the others attempt to head for the Digital World. At that moment, a Digivice appears in the hand of Daisuke, who is with them. And when Daisuke touches the Digi-Egg of Courage—an egg no one had ever been able to move—the curtain rises on a brand-new adventure.“Magical DoReMi #” – Episode 1: Doremi Becomes a Mom!?Story summaryThe Ojamajo girls head to the Witch World to deliver something Majolica forgot, but they accidentally wander into the Queen’s garden, where they witness a baby being born from a single rose.According to the rules of the Witch World, the person who first sees the newborn baby must take care of it for one year. And so, a new chapter in the Ojamajo girls’ lives begins.(4) Event Navigator: Noriko Namiki (voice actress)(5) No. of participants: Approximately 30 (come and go as you wish)(6) Participation fee: Free*Please sit in the allocated seating area.*Photos, video recordings, and sound recordings inside the venue are prohibited on the day of the events.*Guests may be required to stand if all the seats are filled.*Seats may be moved after each screening.*Staff will take photographs for use in Anime Tokyo Station publicity and reporting materials.By participating, it is assumed that you understand and agree to these conditions.*Please follow staff guidance when participating.For details, please visit https://animetokyo.jp/en/archives/events/events52/Details of the Special Lecture Series “The Power to Create Anime: Nine Lessons for the Future”(1) Date and time:Session 4 —Saturday, December 20, 2025, 15:00–17:00Hiroyuki Kakudo (Animation Director, known for Digimon Adventure 02)Application: https://forms.office.com/r/aJpjFwdfeVSession 5 —Saturday, January 17, 2026, 15:00–17:00Hiromi Seki (Producer, Planning Department, Toei Animation; known for Magical DoReMi #)Application: Please check the official website.*Please note that session times are subject to change.(2) Venue: Special Event Hall, 14th Floor, Anime Tokyo Station (Tokyu East 5, 2-25-5 Minami-Ikebukuro, Toshima City, Tokyo)(3) Participation fee: Free(4) Eligible age: High school students and above*Non-Japanese nationals who understand Japanese are also eligible to participate.(5) No. of participants: 50 per session (advance application and lottery)(6) How to apply: Please apply for each session via the application URL provided on the event page of the Anime Tokyo Station official website.Event page: https://animetokyo.jp/en/archives/events/workshop50/*Please check each session’s application page for the application deadline.*Please read the notes on the application page before applying.*For cancellations or related inquiries, please contact us at the email address below.Contact: info@animetokyo.jpCharacter Meet-and-Greet Details“Magical DoReMi #” — Doremi-chan(1) Schedule:January 25, 2026 (Sun.)(2) Time:Session 1: 12:00–12:20Session 2: 14:00–14:20Session 3: 16:00–16:20(3) Venue:1st floor, Anime Tokyo Station(4) No. of participants:One group of 20 persons per session(5) Application date:From December 19 (Fri.), 2025 “Digimon Adventure 02” — Veemon(1) Schedule:February 1, 2026 (Sun.)(2) Time:Session 1: 12:00–12:20Session 2: 14:00–14:20Session 3: 16:00–16:20(3) Venue:1st floor, Anime Tokyo Station(4) No. of participants:One group of 20 persons per session(5) Application date:From December 19 (Fri.), 2025 Notes- Date, time, and contents are subject to change.- Please check the official website and social media accounts for the application URL and the latest updates.- Please fill in the application after reading and understanding the notes on the application page.Venue OverviewName:Anime Tokyo Station (also known as "Anime Tokyo")Location:Floors B1 to 2F of Tokyu East 5 (2-25-5 Minami-Ikebukuro, Toshima-ku, Tokyo)*4 minutes on foot from Ikebukuro StationHours:11:00 a.m. to 7:00 p.m. (last admission: 6:45 p.m./ Special exhibitions close: 6:30 p.m.)Closed: Mondays*If Monday falls on a holiday, the venue will be open on Monday and closed on the following dayNew Year's holiday periodMay be closed on other daysPlease check the venue website before coming.Admission fee:FreeWebsite:https://animetokyo.jp/en/sns:X|https://x.com/animetokyo_info (@animetokyo_info)Instagram|https://www.instagram.com/animetokyostation/ (@animetokyostation)YouTube|https://www.youtube.com/@AnimeTokyoStationInquiries regarding this press releasePublic Relations Office of "Anime Tokyo Station" (Kyodo PR)Contact person: Miri YasudaE-mail: animetokyo-pr@kyodo-pr.co.jp Press release: http://www.acnnewswire.com/docs/files/20251212.pdf Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion ACN Newswire

HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion

HONG KONG, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – Hong Kong’s exports are expected to grow by between 8% and 9% in 2026, according to figures releaased today by the Hong Kong Trade Development Council (HKTDC). The forecast forms part of the HKTDC’s annual Export Outlook report and follows on from the city’s better-than-anticipated 2025 export performance.For 2026, this sustained growth is set to be driven by robust demand for AI-related electronics products. According to the findings of the recently-released HKTDC 4Q25 Export Confidence Index, the majority of exporters (53.2%) see rising demand for AI/new technology-related electronic consumer goods as the factor most likely to boost their 2026 business. This is seen as crucial given that the electronics sector, overall, accounts for more than 70% of Hong Kong’s total export value.Heightened uncertainty giving way to greater clarityThese upbeat figures are remarkable given the high year-on-year comparison base from 2025. This is because many exporters sought to frontload orders in a bid to complete shipments before the imposition of the much-anticipated US tariffs.Detailing the upshot of the tariff-related trade upheavals in particular, Irina Fan, Director of HKTDC Research, said: “While 2025 proved to be a year of heightened uncertainty, 2026 should be a year of greater clarity on global trade. With the Chinese Mainland and the US having come to a trade agreement in November, – some four months after many other nations had struck their own deals with the Trump administration – US tariffs are no longer among Hong Kong exporters' three biggest 2026 concerns.”Fan did, however, acknowledge that uncertainties remain ahead. She said that as US imports from different countries are subject to different levels of tariffs, business leaders around the world will be looking to re-organise their activities to optimise any cost advantages.Outlining what this will mean within the Asia-Pacific region, Fan said: “Chinese Mainland exports to the US will be subject to 20% reciprocal tariff rate until November 2026 [1]. This comparatively low additional tariff puts China-based suppliers, many with more mature and highly productive supply chains, on par with their Southeast Asia counterparts, while giving them a significant advantage over any country subject to a higher tariff rate.”Multi-sector expectation of continued export expansionUnderpinning Hong Kong’s anticipated 2026 export expansion are the findings of the HKTDC Export Confidence Index 4Q25, which was also released today. The two key measures of this long-established quarterly metric –the Current Performance Index (51.4) and the Expectation Index (51.9) – have both stayed above the 50-point watershed level, a clear indication that future export growth is expected.Commenting on the findings of the 4Q25 survey, Kenneth Lee, Head of the HKTDC Research’s Special Project and Business Advisory Section, said: “When it comes to expansion plans over the next two-year period, Asia remains very much the focus. For 42.0% of respondents, the Chinese Mainland was the highest priority market, followed by the rest of Asia (30.3%) and the ASEAN bloc (18.9%). By industry, exporters in almost every sector saw scaling up their activities on the Chinese Mainland as their priority.”Beyond the headline findings of the survey, a more detailed analysis highlights good news for Hong Kong exporters in terms of both individual market prospects and the likely future success of most of the city’s key industry sectors.Positive sentiments for major markets and key industry sectorsIn specific terms, turning to the Market Expectation Sub-Index, the Chinese Mainland (57.2) and the ASEAN bloc (57.0) are still considered to have significant growth potential. Predictably, this was less the case for the US (down 1.4 to 38.0), with the uncertainties in its trade environment continuing to unsettle Hong Kong exporters.Turning to individual industries, a number of sectors have expansionary expectations for the year ahead (i.e. had a relevant index reading of 50 or more). Topping the list is Jewellery (54.8), followed by Electronics (52.4), Timepieces (51.6) and Equipment/Materials (51.1).Despite such overall positive sentiments, the survey also points out the possibility that a number of challenges may lie ahead. Most notably, it cited rising labour and production costs (53.9%), growing logistics challenges (38.8%) and declining overseas orders on account of the general economic slowdown (38.2%) as potential future concerns.[1] On top of Trump 1.0 tariffs of ~20% on averageReferencesHong Kong 2026 Export Outlook: Sustained AI Product Demand Set to Drive 8-9% Growth Over Coming Year:https://research.hktdc.com/en/article/MjE4ODc2Mzk2NwHKTDC Export Confidence Index 4Q25: End-of-Year Figures Indicate Positive Expansion Prospects:https://research.hktdc.com/en/article/MjE4ODYyNTQwNwHKTDC Research website: https://research.hktdc.com/en/ Photo download: https://bit.ly/4oJPrPRHKTDC Director of Research Irina Fan (right) and HKTDC Section Head, Special Project & Business Advisory, Kenneth Lee (left) announced the HKTDC Export Confidence Index for 2025’s fourth quarter at a press conference todayHKTDC Director of Research Irina FanHKTDC Section Head, Special Project & Business Advisory Kenneth LeeMedia enquiriesPlease contact the HKTDC’s Communication and Public Affairs Department:Navin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgAgnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion ACN Newswire

2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion

HONG KONG, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – Hong Kong’s exports are expected to grow by between 8% and 9% in 2026, according to figures releaased today by the Hong Kong Trade Development Council (HKTDC). The forecast forms part of the HKTDC’s annual Export Outlook report and follows on from the city’s better-than-anticipated 2025 export performance.For 2026, this sustained growth is set to be driven by robust demand for AI-related electronics products. According to the findings of the recently-released HKTDC 4Q25 Export Confidence Index, the majority of exporters (53.2%) see rising demand for AI/new technology-related electronic consumer goods as the factor most likely to boost their 2026 business. This is seen as crucial given that the electronics sector, overall, accounts for more than 70% of Hong Kong’s total export value.Heightened uncertainty giving way to greater clarityThese upbeat figures are remarkable given the high year-on-year comparison base from 2025. This is because many exporters sought to frontload orders in a bid to complete shipments before the imposition of the much-anticipated US tariffs.Detailing the upshot of the tariff-related trade upheavals in particular, Irina Fan, Director of HKTDC Research, said: “While 2025 proved to be a year of heightened uncertainty, 2026 should be a year of greater clarity on global trade. With the Chinese Mainland and the US having come to a trade agreement in November, – some four months after many other nations had struck their own deals with the Trump administration – US tariffs are no longer among Hong Kong exporters' three biggest 2026 concerns.”Fan did, however, acknowledge that uncertainties remain ahead. She said that as US imports from different countries are subject to different levels of tariffs, business leaders around the world will be looking to re-organise their activities to optimise any cost advantages.Outlining what this will mean within the Asia-Pacific region, Fan said: “Chinese Mainland exports to the US will be subject to 20% reciprocal tariff rate until November 2026 [1]. This comparatively low additional tariff puts China-based suppliers, many with more mature and highly productive supply chains, on par with their Southeast Asia counterparts, while giving them a significant advantage over any country subject to a higher tariff rate.”Multi-sector expectation of continued export expansionUnderpinning Hong Kong’s anticipated 2026 export expansion are the findings of the HKTDC Export Confidence Index 4Q25, which was also released today. The two key measures of this long-established quarterly metric –the Current Performance Index (51.4) and the Expectation Index (51.9) – have both stayed above the 50-point watershed level, a clear indication that future export growth is expected.Commenting on the findings of the 4Q25 survey, Kenneth Lee, Head of the HKTDC Research’s Special Project and Business Advisory Section, said: “When it comes to expansion plans over the next two-year period, Asia remains very much the focus. For 42.0% of respondents, the Chinese Mainland was the highest priority market, followed by the rest of Asia (30.3%) and the ASEAN bloc (18.9%). By industry, exporters in almost every sector saw scaling up their activities on the Chinese Mainland as their priority.”Beyond the headline findings of the survey, a more detailed analysis highlights good news for Hong Kong exporters in terms of both individual market prospects and the likely future success of most of the city’s key industry sectors.Positive sentiments for major markets and key industry sectorsIn specific terms, turning to the Market Expectation Sub-Index, the Chinese Mainland (57.2) and the ASEAN bloc (57.0) are still considered to have significant growth potential. Predictably, this was less the case for the US (down 1.4 to 38.0), with the uncertainties in its trade environment continuing to unsettle Hong Kong exporters.Turning to individual industries, a number of sectors have expansionary expectations for the year ahead (i.e. had a relevant index reading of 50 or more). Topping the list is Jewellery (54.8), followed by Electronics (52.4), Timepieces (51.6) and Equipment/Materials (51.1).Despite such overall positive sentiments, the survey also points out the possibility that a number of challenges may lie ahead. Most notably, it cited rising labour and production costs (53.9%), growing logistics challenges (38.8%) and declining overseas orders on account of the general economic slowdown (38.2%) as potential future concerns.[1] On top of Trump 1.0 tariffs of ~20% on averageReferencesHong Kong 2026 Export Outlook: Sustained AI Product Demand Set to Drive 8-9% Growth Over Coming Year:https://research.hktdc.com/en/article/MjE4ODc2Mzk2NwHKTDC Export Confidence Index 4Q25: End-of-Year Figures Indicate Positive Expansion Prospects:https://research.hktdc.com/en/article/MjE4ODYyNTQwNwHKTDC Research website: https://research.hktdc.com/en/ Photo download: https://bit.ly/4oJPrPRHKTDC Director of Research Irina Fan (right) and HKTDC Section Head, Special Project & Business Advisory, Kenneth Lee (left) announced the HKTDC Export Confidence Index for 2025’s fourth quarter at a press conference todayHKTDC Director of Research Irina FanHKTDC Section Head, Special Project & Business Advisory Kenneth LeeMedia enquiriesPlease contact the HKTDC’s Communication and Public Affairs Department:Navin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgAgnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China ACN Newswire

CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China

SHENZHEN, Dec 11, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke.With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms.Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals.The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients.More Information about Y-3 for InjectionThe pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects.The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability.On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent.About StrokeAccording to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001.2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Eisai Rated “A”, the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year ACN Newswire

Eisai Rated “A”, the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year

TOKYO, Dec 11, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that it has been selected for the highest-rated “A” List in the fields of Climate Change and Water Security for 2025 by the global environmental non-profit organization CDP.(1) This marks the second consecutive year the company has been named in both categories of the CDP’s A List.Based on Eisai’s Future Creation Strategy(2) (Sustainability Strategy), the company is committed to addressing material issues and social challenges over the mid- to long- term, with the aim of contributing to sustainable corporate growth and the sustainable development of society. In the field of environmental conservation, Eisai has identified “Business activities with consideration for the global environment” as one of our material issues. Based on the Eisai Network Companies Environmental Policy, Eisai is promoting responses to climate change and sustainable water use as environmental activities across the group.As part of its climate change response, Eisai is working towards the realization of a decarbonized society, including obtaining approval for the SBT 1.5'C target from the Science Based Targets (SBT) Initiative in FY2023, and participating in the Japan Climate Initiative (JCI) Race to Zero Circle, which calls for achieving net zero by 2050. Through these efforts, Eisai is contributing to the reduction of greenhouse gas emissions.(3) Regarding sustainable water use, Eisai has set its mid-term target to reduce water withdrawal across the company by 7%(4) by FY2030 compared to FY2023, promoting efficient use of water resources, including recycling of laboratory wastewater and rainwater. Please refer to Eisai’s website for more detailed information about its environmental activities.To realize the human health care (hhc) concept, conservation of the global environment is essential. Eisai is committed to empowering people to “realize their fullest lives” through initiatives addressing climate change and the promotion sustainable water use.(1) A non-profit organization headquartered in the UK. The organization operates the world’s only independent environmental information disclosure system(2) Please refer to Eisai Value Creation Report (https://www.eisai.com/ir/library/annual/pdf/pdf2025vcr.pdf)(3) Please refer to the following news release for details. EISAI TO BOOST INITIATIVES ON GREENHOUSE GAS REDUCTION, AIMING TO ACHIEVE NET ZERO BY 2050 (https:/www.eisai.com/news/2024/news202412.html)(4) Per unit of salesMedia Inquiries:Public Relations Department,Eisai Co., Ltd.+81-(0)3-3817-5120 Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
Focus Graphite Achieves 99.9996 wt.% Ultra-High Purity and 2.03 ppm EBC in Follow-On Testing ACN Newswire

Focus Graphite Achieves 99.9996 wt.% Ultra-High Purity and 2.03 ppm EBC in Follow-On Testing

5N+ Purity and On-Spec EBC Confirm Lac Knife's Potential as a North American Source of Ultra-High-Performance Graphite ApplicationsOttawa, Ontario--(ACN Newswire via SeaPRwire.com - December 11, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and innovator of next-generation battery technology, is pleased to announce that follow-on purification and elemental analysis of material from its Lac Knife deposit (concentrate Lot ID: GN25073005) achieved 99.9996 wt.% ("5N+") and an Equivalent Boron Concentration ("EBC") of 2.03 ppm, confirming the material is within nuclear-grade specification and meets the technical thresholds required for several high-value advanced materials markets.The test work, conducted using electrothermal purification with no halogen gases (e.g. chlorine) or acids, produced this ultra-pure result in two (2) hours, further validating a chemical-free, environmentally advantageous pathway compared to conventional purification methods. These results directly support Focus's ongoing engineering and scale-up programs funded under Natural Resources Canada's ("NRCan") Global Partnerships Initiative ("GPI"), under which the Company was awarded a non-repayable contribution of up to $14.1 million to accelerate North American capacity for clean, advanced material processing.Subsequent elemental analysis calculated in accordance with ASTM C1233-15: Standard Practice for Determining Equivalent Boron Contents of Nuclear Materials yielded an Equivalent Boron Concentration ("EBC") of 2.03 ppm (Table 1), which falls below the critical 3 ppm threshold often cited for nuclear-grade graphite applications. The calculated EBC value is the most critical test of purity for nuclear industry use.These results suggest that Lac Knife graphite has the potential to serve markets requiring ultra-high-purity large and jumbo flake natural graphite. Achieving both 5N+ purity and a high proportion of large-flake concentrate is uncommon in the natural graphite industry and may provide Focus with opportunities in markets historically reliant on synthetic graphite or otherwise inaccessible to peers. These findings are consistent with peer-reviewed research published in ACS Omega ("Ultrahigh Temperature Purification of Graphite for the Development of a Continuous Process," ACS Omega, 2025), conducted by American Energy Technologies Company ("AETC") and NRCan, which demonstrated that ultrahigh-temperature purification of natural Canadian graphite can produce materials exhibiting purity and crystallinity suitable for advanced applications. Focus's ongoing testwork indicates that residual impurities appear primarily on the surface of the graphite flake—as evidenced by ultra-fine features observed through scanning electron microscopy—suggesting that purification efficiency is strongly influenced by surface cleaning dynamics rather than structural defects within the carbon lattice.Dean Hanisch, Chief Executive Officer of Focus commented, "These results validate Lac Knife as one of the rare unique natural graphite deposits capable of competing in high margin advanced technological markets and as a potential alternative to synthetic materials that are more expensive and have a larger environmental impact. With support from Canada's Federal Government, through Natural Resources Canada's Global Partnerships Initiative, we are now positioned to accelerate our scale-up work and unlock commercial pathways across nuclear energy, defense systems, graphene production, and next-generation electronics."Lac Knife graphite's combination of ultra-high purity and large flake distribution positions it for a range of advanced industrial, clean energy, and high-technology applications.Unlocking Advanced Markets Beyond NuclearBeyond nuclear applications, the ultra-high purity and medium-grain morphology of Lac Knife graphite position the material as a strategic feedstock for several advanced technology markets facing supply shortages, performance bottlenecks, and increasing scrutiny over material purity.Graphene & Few-Layer Graphene (FLG) ProductionIn the graphene sector, precursor quality is the primary determinant of performance. Impurities commonly found in natural graphite—typically 0.5-1 microns in size, or roughly one thousand (1000) times thicker than a graphene layer—are known to disrupt electrical, thermal, and mechanical properties unless fully removed. Lac Knife's 5N+ purity eliminates these defects at the source, allowing the flake to exfoliate cleanly into high-value graphene structures.Peer-reviewed research published in Carbon ("Influence of graphite geography on the yield of mechanically exfoliated few-layer graphene," Carbon, 2023) demonstrates the significance of geological origin in FLG production. In follow-on AETC—Yale University testing based on the methodologies outlined in that study, Lac Knife graphite achieved a record-high few-layer graphene yield of 22% ± 3%, outperforming all other natural samples evaluated and showing exfoliation behavior that synthetic graphite could not replicate.Taken together, these results position Lac Knife as one of the few North American natural flake sources capable of supplying advanced graphene markets, including conductive coatings, EMI-shielding materials, flexible electronics, sensors, and next-generation energy storage systems.Defence: IR Obscuration & Countermeasure SystemsThe defence sector presents another major opportunity. Modern warfare increasingly requires materials capable of obscuring both visible and infrared signatures. Traditional obscurants—such as bronze flakes, titanium dioxide, and red phosphorus—pose toxicity, safety, and performance challenges. High-purity graphite and graphene derived from Lac Knife offer a lightweight, non-toxic, and thermally stable alternative capable of generating rapid-dispersion and longer-lasting obscurant clouds.These materials are applicable to 40 mm muzzle-blast cartridges, airburst obscuration rounds for UAVs and rotorcraft, countermeasure dispenser systems, and naval surface-ship defence platforms. The U.S. Department of War currently procures graphene-based obscurants at approximately US$30,000 per ton, reflecting both strategic importance and limited supply. Lac Knife's purity is essential here, as impurities directly interfere with graphene formation and degrade obscurant performance.Stealth Coatings & Electromagnetic Protection SystemsUltra-high purity graphite also plays a critical role in stealth coatings and electromagnetic protection systems. Engineered systems operating across the 400 MHz to 30 GHz spectrum require materials that deliver highly reproducible electrical conductivity, thermal stability, and particle uniformity.These coatings and composites are used in radar-absorbing structures for stealth UAVs, thermal-vision targeting systems, and a range of low-observable technologies. Because deviations in graphite purity can compromise system reliability or operator safety, defence and shielding markets pay substantial premiums—often up to US$50,000 per ton—for 5N-grade material. Lac Knife's combination of purity, consistency, and grain structure aligns closely with these stringent requirements and allows for further refinement into fine, superfine, ultrafine, or microfine grades without compromising integrity.Critical Infrastructure Hardening (HEMP, IEMI and Geomagnetic Storms)The same purity advantages extend into critical infrastructure protection. As governments and utilities work to harden electrical grids, substations, and 5G networks against high-altitude electromagnetic pulses (HEMP), intentional electromagnetic interference (IEMI), and severe geomagnetic storms, materials must perform reliably across high-frequency ranges and under extreme operating conditions.Graphite-based shielding and coatings designed for these systems rely on predictable, reproducible material behavior—standards that only ultra-high purity graphite can meet. Lac Knife's 5N+ output offers the reliability required for these mission-critical applications.Additional High-Value Markets Enabled by 5N+ PurityIn addition to these strategic sectors, Lac Knife's purity profile and particle characteristics also unlock potential in several high-value industries, including thermal management components for semiconductors and LEDs, high-pressure synthetic diamond production, PEM and SOFC fuel-cell bipolar plates, and laboratory-grade graphite consumables where contamination must be tightly controlled. In each of these markets, ultra-high purity reduces defects, increases stability, and improves overall system performance, enabling natural graphite to compete directly with synthetic alternatives.Next Steps in Technical ValidationFocus is advancing a comprehensive technical qualification program to further define Lac Knife's suitability for nuclear and advanced material markets. Ongoing nuclear graphite testing includes detailed characterization of particle size distribution, compressibility, electrical resistivity, and coefficient of friction—parameters that determine whether a graphite material can perform reliably under the thermal, mechanical, and irradiation stresses present in high-temperature reactor environments. The Company expects to fabricate and evaluate near-net-shape graphite bricks, an essential step toward assessing Lac Knife material in full-scale core component geometries and within ASME Division 5 design criteria.In parallel, Focus is extending its validation program—supported through NRCan's Global Partnerships Initiative ("GPI")—advanced materials markets. Current work programs under consideration include assessing Lac Knife graphite as a precursor for high-yield graphene, nano-wafer substrates, thin-film semiconductors, next-generation electronic components, and aerospace composites, including unmanned aerial systems (UAS). These sectors demand highly reproducible, ultra-high-purity carbon materials traditionally sourced from synthetic graphite. Early results indicate that Lac Knife's 5N+ natural graphite may offer a technically competitive—and potentially more sustainable—North American alternative to synthetic feedstocks across multiple high-value applications.ElementImpurity Limit (mg/kg)EBC FactorEBC CalculationAg0.050.00830.000415Al10.00010.0001B0.1210.12Ca0.360.00020.000072Cd50.31721.586Cl1.50.01340.0201Co0.050.00890.00445Cr0.120.00080.000096Cu0.250.00080.0002Dy0.050.08180.00409Eu0.10.4250.0425Fe0.210.00060.000126Gd0.054.39910.219955K0.60.00080.00048Li0.030.14390.004317Mn0.120.00340.000408Mo0.150.00040.00006Na0.0850.00030.0000255Ni0.180.00110.00198S1.40.00020.00028Si1.460.00010.000146Sm0.050.53360.02668Th0.010.00050.000005Ti0.530.00180.000954U0.050.00050.000025V0.080.00140.000112 Total 2.0277895 Table 1: EBC Calculation, Thermally Purified Lac Knife Lot ID: GN250730005Figure 1: Particle Size Distribution, Thermally Purified Lac Knife Lot ID: GN250730005To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/277711_279dc9a07490cbe0_001full.jpgTap DensityScott VolumeSurface AreaLOI g/ccg/ccm2 /gWt. % C0.60.41.499.9996 Table 2: Data, Thermally Purified Lac Knife Lot ID: GN250730005% TileSize (um)D10105.2D50337.3D90673.8MV368.5 Table 3: Data (2), Thermally Purified Lac Knife Lot ID: GN250730005Qualified PersonDr. Joseph Doninger, Director of Technology and Manufacturing for Focus Graphite, is the Qualified Person ("QP") as defined under National Instrument 43-101 - Standards of Disclosure for Mineral Projects. Dr. Doninger has reviewed and approved the technical information contained in this news release. Dr. Doninger is a chemical engineer and the developer or co-developer of multiple U.S., European, and Canadian patents relating to carbon processing technologies and purification equipment. He has authored or co-authored more than two dozen technical papers and studies on graphite composite anodes, carbon-based materials for electrochemical energy storage systems, and advanced graphite for lithium-ion batteries.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.com.LinkedIn: https://www.linkedin.com/company/focus-graphite/ X: https://x.com/focusgraphiteInvestors Contact: Dean Hanisch CEO, Focus Graphite Inc. dhanisch@focusgraphite.com +1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the anticipated performance and downstream applicability of ultra-high-purity graphite derived from the Lac Knife project; the potential for 5N+ purification results and nuclear-grade Equivalent Boron Concentration ("EBC") values to be replicated at larger scale; the implications of testwork conducted under Natural Resources Canada's Global Partnerships Initiative ("GPI") and the expected outcomes of related engineering, scale-up, and validation programs; the ability of Lac Knife graphite to meet nuclear, graphene, defense, electromagnetic shielding, thermal management, semiconductor, and other advanced material specifications; the potential commercial pathways associated with supplying high-purity natural graphite as an alternative to synthetic graphite; and the Company's strategy to position itself within North American supply chains for clean energy, advanced manufacturing, aerospace, and critical infrastructure markets.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277711 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Dr. Teck Lim Chia, Chairman and CEO of CBL International, Honored at the Prestigious Directors of the Year Awards ACN Newswire

Dr. Teck Lim Chia, Chairman and CEO of CBL International, Honored at the Prestigious Directors of the Year Awards

KUALA LUMPUR, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – CBL International Limited (NASDAQ: BANL) (the “Company” or “CBL”), the listing vehicle of the Banle Group (“Banle” or “the Group”) is honored to announce that Dr. Teck Lim Chia, Chairman and Chief Executive Officer of CBL International Limited, has been selected as an Awardee in the Directors of the Year Awards – Listed Companies Executive Directors category, presented by the Hong Kong Institute of Directors (HKIoD).This esteemed accolade follows a comprehensive evaluation by an independent panel of judges comprising senior business leaders, governance experts, and institutional investors. The award recognizes Dr. Chia’s outstanding contributions to corporate governance, exemplary board leadership, and his proven track record in driving sustainable value creation for shareholders and stakeholders.The HKIoD Directors of the Year Awards are among Asia’s most respected honors in corporate governance. Awardees are chosen based on demonstrated excellence in strategic oversight, ethical leadership, transparency, and long-term sustainable performance—all hallmarks of Dr. Chia’s tenure at CBL International. As Chairman and CEO, Dr. Chia has led the Group through a period of transformative growth while embedding governance excellence into the company’s core. Under his stewardship, CBL has strengthened its investor relations framework, enhanced ESG disclosures, deepened stakeholder engagement, and maintained rigorous compliance with international standards throughout its expansion across Asia Pacific, Europe, Central America and Africa.In accepting the award, Dr. Teck Lim Chia said: “I am deeply humbled and grateful to receive this prestigious recognition from the Hong Kong Institute of Directors. This honor belongs not to me alone, but to our entire board, management team, and employees who share a relentless commitment to integrity, innovation, and responsible growth. At CBL, we believe governance is not a box to check — it is the compass that guides every decision. I will continue to lead with purpose, accountability, and vision, always placing the long-term interests of our stakeholders first.”The Board of CBL International expressed its pride in Dr. Chia’s achievement: “Dr. Chia’s leadership has been instrumental in shaping CBL into a globally recognized, governance-forward enterprise. His ability to balance strategic ambition with disciplined oversight exemplifies what modern corporate leadership should be. We congratulate him on this well-deserved honor.”Photo caption: Dr. Teck Lim Chia (right), Chairman and CEO of CBL International Limited, honored at the Directors of the Year Awards – Listed Companies Executive Directors category by the Hong Kong Institute of Directors (HKIoD).Photo caption: The trophy for Directors of the Year Awards – Listed Companies Executive Directors category by the Hong Kong Institute of Directors (HKIoD).About the Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistics company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with a one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in 65 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam. The Group actively promotes the use of sustainable fuels and has been awarded the ISCC EU and ISCC Plus certifications.For more information about our Company, please visit our website at: https://www.banle-intl.com. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

Cloudbreak Pharma Soars 80%+ on Multiple Catalysts, Driving Value Re-Rating

HONG KONG, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – Since 2025, driven by both policy tailwinds and fundamental strengths, the innovative drug sector in the Hong Kong stock market has experienced a valuation recovery. Although it experienced some correction in the second half due to external environmental factors, its overarching growth logic remains intact. Institutional analysis indicates that innovative drugs continue to represent the clearest industry trend within the pharmaceutical sector, with promising development prospects ahead.Among the players, Cloudbreak Pharma (2592.HK), a biotech company focused on ophthalmology, has recently demonstrated strong stock performance. As of December 9, its share price closed at HK$8.24, having accumulated a gain of over 80% in approximately two weeks, and making it a standout "star stock" in the capital markets. This impressive performance is not coincidental but rather the inevitable result of multiple positive catalysts converging, including breakthroughs in its core product pipeline, enhancements to its global intellectual property (IP) layout, and an upgrade of its core management team.Securing Another Victory in Patent Layout, Accelerating Commercialization of Core ProductOn November 27, Cloudbreak Pharma's wholly-owned subsidiary, ADS Therapeutics LLC, successfully secured two core patents in Japan and Europe. Both patents relate to ophthalmic topical compositions and their uses for the core product CBT-009, laying a legal foundation for its global commercialization.As a novel atropine ophthalmic formulation for treating myopia in children and adolescents aged 5 to 19, CBT-009, with its unique non-aqueous formulation design, demonstrates potential advantages over traditional aqueous formulations in terms of drug stability, safety, and patient tolerability, positioning it as a potential best-in-class product. Currently, the product's development is progressing steadily. It received U.S. FDA approval to initiate Phase 3 clinical trial in September 2024. Juvenile animal toxicity studies in China commenced in February 2025, and preparations for Phase 3 clinical trial are actively underway.The grant of these patents in Japan and Europe not only strengthens the global IP portfolio for CBT-009, but will also accelerate its commercialization process. Leveraging patent protection, the Company has the potential to establish partnerships with global pharmaceutical giants to advance the product's production and distribution in key markets like Japan and Europe, accelerating global market penetration. Given the severity of the global adolescent myopia issue, CBT-009 is expected to become a core engine for the Company's future performance growth.Pipeline Progress Across Multiple Fronts; CBT-004 Advances Towards Phase 3Beyond CBT-009, another promising drug candidate from Cloudbreak Pharma, CBT-004, has also reached a significant milestone. As a potential first-in-class drug for vascularized pinguecula, CBT-004 uses Multi-Kinase Inhibitor targeting Vascular Endothelial Growth Factor Receptor (VEGFR) and Platelet-Derived Growth Factor Receptor (PDGFR). According to the Company's latest disclosures, CBT-004 yielded positive results in a Phase 2 clinical trial evaluating its safety and efficacy in treating pinguecula. The Company has begun advancing its Phase 3 clinical development and is scheduled to meet with the United States Food and Drug Administration (the “FDA”) on December 10 (Pacific Standard Time, PST) at an End-of-Phase 2 meeting to establish a regulatory pathway for potential approval.It is understood that there are currently no approved drugs globally specifically for treating vascularized pinguecula. Existing treatment options mostly offer temporary symptomatic relief, leaving significant unmet clinical needs. Should CBT-004 successfully complete development and gain approval, it would become the first targeted therapy, rapidly capturing market share with its unique efficacy advantages. This would create a new revenue stream for the Company while further solidifying its leading position in the field of ophthalmic innovative drugs.Strengthened Executive Team Elevates Commercialization CapabilitiesThe success of innovative drugs relies not only on R&D prowess but also on robust commercialization capabilities to realize their value. On December 1, 2025, Cloudbreak Pharma announced the official appointment of Mr. Michael Rowe as its new Chief Business Officer (CBO), injecting key momentum into the Company's global commercial strategy.Public information shows that Mr. Michael Rowe possesses substantial hands-on commercialization experience across senior management, marketing, sales management, and clinical operations. He is particularly skilled in driving organizational efficiency and achieving breakthroughs in innovative business areas. His industry resources and operational capabilities are expected to bring comprehensive enhancements to the Company.This executive appointment coincides with Cloudbreak Pharma’s core products entering a critical preparatory phase for commercialization. Mr. Michael Rowe's joining will strengthen the Company's business development capabilities in European and American markets, accelerating the construction of its global commercial footprint. Currently, through collaborations with companies such as Grand Pharmaceutical Group and Santen, Cloudbreak Pharma has established a commercialization foundation in Greater China and the Asia-Pacific region (excluding China). With the new CBO onboard, the Company is poised to further expand its global partnership network, optimize commercialization strategies, and provide robust support for the market entry of its multiple core products.With Sustained High Industry Growth, Valuation Re-rating Potential RemainsIn recent years, the global incidence of ophthalmic diseases has continued to rise. Conditions like pterygium and adolescent myopia affect hundreds of millions of patients, while the supply of innovative drugs in related treatment areas remains severely inadequate, indicating a vast unmet market need. Concurrently, governments worldwide are increasing support for pharmaceutical innovation, providing a favorable policy environment for high-quality innovative drug companies. Within the Hong Kong stock market, the innovative drug sector is experiencing a favorable trend of valuation re-rating. Companies with solid R&D pipelines, clear commercialization pathways, and core competitiveness are seeing gradually rising valuation expectations.As an innovative drug company dedicated to ophthalmology, Cloudbreak Pharma has built a rich pipeline covering 8 drug candidates targeting major diseases in both the anterior and posterior segments of the eye, forming a diversified product matrix. With steady progress in R&D and an increasingly refined global commercialization strategy, the Company already exhibits scarce growth attributes. The recent short-term surge in its stock price, catalyzed by multiple positive factors, is merely the beginning of value release. As these favorable initiatives are further implemented and pipeline value continues to be realized, Cloudbreak Pharma is poised to achieve dual enhancement in both performance and valuation. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Nasdaq Verafin Joins Global Anti-Scam Alliance ACN Newswire

Nasdaq Verafin Joins Global Anti-Scam Alliance

THE HAGUE, NETHERLANDS, Dec 10, 2025 - (ACN Newswire via SeaPRwire.com) - The Global Anti-Scam Alliance (GASA) is pleased to announce that Nasdaq Verafin has joined GASA as a Foundation Member, strengthening the global effort to combat scams, financial crime, and digital fraud. As fraud tactics continue to evolve across borders and digital channels, cross-sector collaboration has become essential to protecting consumers and building safer financial ecosystems.Nasdaq Verafin's participation marks a meaningful step forward in the shared mission to advance trust, transparency, and resilience across the globe. In addition to joining the global effort, Nasdaq Verafin will join both the Brazil and Mexico chapters of GASA to partner with stakeholders across the financial ecosystem in Latin America, bolstering regional initiatives to combat financial crime."Criminals are innovating at an unprecedented rate, taking advantage of information siloes and the shortcomings of legacy technology to avoid detection. We are at an inflection point in the fight against financial crime, one that requires the entire ecosystem to come together, leveraging the power of collective intelligence to strengthen our defenses and better protect consumers around the globe. We look forward to partnering closely with the Global Anti-Scam Alliance to share innovative solutions, intelligence, and global expertise to the unique challenges financial institutions in Brazil and Mexico face," said Mauriceo Castanheiro, Head of International Payments Fraud at Nasdaq Verafin.Nasdaq Verafin is a global leader in financial crime management technology solutions, trusted by more than 2,700 financial institutions around the globe. The company's innovative approach combines consortium data, AI, and machine learning to deter, detect, and prevent criminal activity. Nasdaq Verafin's consortium approach uncovers hidden risks across the financial system, leveraging data and insights from across 800 million counterparties to improve fraud detection and prevention while reducing false positives."Having Nasdaq Verafin join the Global Anti-Scam Alliance as a Foundation Member is a milestone for our organization and for the global fight against scams. Their deep expertise in leveraging technology to more efficiently and effectively detect criminal activity brings a new level of insight and influence to our mission. With Nasdaq Verafin's partnership, and their representatives joining the boards of our Brazil and Mexico Chapters, we are strengthening our ability to connect global knowledge with local action. Together, we can help shape stronger policies, accelerate industry collaboration, and build the foundations of a scam free future." said Jorij Abraham, Managing Director of GASA."The addition of Nasdaq Verafin as a Foundation Member is not only a milestone for the Brazil Chapter, it is a strong endorsement of the relevance of our market and the seriousness of the work we have been building from day one. We are starting our journey already alongside a globally recognized institution known for excellence, innovation, and a deep commitment to integrity. This partnership strengthens our ability to translate global expertise into local impact and accelerates our mission to raise the standard of collaboration in the fight against scams and financial crime in Brazil." said Renata Salvini, Chapter Director for Brazil."With 76 percent of Mexican adults victimized by scams and 139 billion pesos lost annually, according to the 2025 State of Scams in Mexico Report, 2026 will be devastating. AI democratized productivity but industrialized fraud, this isn't a prediction, it's a countdown. Combating this epidemic requires integrated defenses where early detection triggers coordinated action across digital platforms, telecommunications, finance, and authorities. Nasdaq Verafin's addition to GASA Mexico bridges the gap between technology and coordination. Without systemic collaboration, our economic system remains vulnerable. This strengthens our multistakeholder commitment to essential stability", added Sissi de la Peña, Chapter Director for Mexico.Through this partnership, Nasdaq Verafin executives will join the Chapter Advisory Boards of GASA Mexico and Brazil. As a Foundation Member, Nasdaq Verafin will collaborate with GASA and its members, bringing insights from more than two decades of stopping financial crime to develop innovative new strategies that protect consumers from fraud and scams.To learn more about Nasdaq Verafin's approach to financial crime detection and prevention, visit www.verafin.com.About the Global Anti-Scam Alliance (GASA)The Global Anti-Scam Alliance is a non profit organization whose mission is to protect consumers worldwide from scams. GASA brings together policymakers, law enforcement agencies, consumer authorities, NGOs, the financial sector, telecom operators, internet platforms, service providers, and cybersecurity organizations to share insights, uncover emerging scams, and promote coordinated action against fraud. Learn more at https://www.gasa.org.About Nasdaq VerafinNasdaq Verafin provides Financial Crime Management Technology solutions for Fraud Detection and Management, AML/CFT Compliance and Management, High Risk Customer Management, Sanctions Screening and Management, and Information Sharing. More than 2,700 financial institutions, representing 11 trillion dollars in collective assets, use Nasdaq Verafin to prevent fraud and strengthen AML/CFT efforts. Visit www.verafin.com to learn more.Cautionary Note Regarding Forward-Looking Statements:Information set forth in this release contains forward-looking statements that involve a number of risks and uncertainties. Nasdaq cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Forward-looking statements can be identified by words such as "will", "may" and other words and terms of similar meaning. Such forward-looking statements include, but are not limited to, statements related to future actions and expected results. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These risks and uncertainties are detailed in Nasdaq's filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q which are available on Nasdaq's investor relations website at http://ir.nasdaq.com and the SEC's website at www.sec.gov. Nasdaq undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.© 2005 Nasdaq, Inc. The Nasdaq logo and the Nasdaq ‘ribbon' logo are the registered and unregistered trademarks, or service marks, of Nasdaq, Inc. in the U.S. and other countries. All rights reserved. This communication and the content found by following any link herein are being provided to you by Nasdaq, Inc. and/or certain of its subsidiaries (collectively, "Nasdaq"), for informational purposes only. Nasdaq makes no representation or warranty with respect to this communication or such content and expressly disclaims any implied warranty under law. At the time of publication, the information herein was believed to be accurate, however, such information is subject to change without notice. Nothing herein shall constitute a recommendation, solicitation, invitation, inducement, promotion, or offer for the purchase or sale of any investment product, nor shall this material be construed in any way as investment, legal, or tax advice, or as a recommendation, reference, or endorsement by Nasdaq.GASA Media ContactMetje van der MeerMarketing Directormetje.vandermeer@gasa.org+31 6 48456282Nasdaq Contact:Nick EghtessadCorporate Communicationsnick.eghtessad@nasdaq.com+1 929 996-8894SOURCE: Global Anti-Scam Alliance Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More